<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A-3
(Amendment No. 3)
(Mark One)
[X] Annual Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 [Fee Required]
For the fiscal year ended December 31, 1996.
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 [No Fee Required]
Commission File No.: 1-8801
GRAHAM-FIELD HEALTH PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Delaware 11-2578230
- ------------------------------------------------- ------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
400 Rabro Drive East, Hauppauge, New York 11788
- ------------------------------------------------- ------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (516) 582-5900
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Name of each exchange on which registered
- -------------------- -----------------------------------------
Common Stock, par value $.025 per share New York Stock Exchange
- --------------------------------------- -----------------------
Securities registered pursuant to Section 12(g) of the Act:
Not Applicable
- --------------------------------------------------------------------------------
(Title of Class)
Indicate by check mark whether registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K (Section 229.405 of this chapter) is not contained
herein, and will not be contained, to the best of registrant's knowledge, in
definitive proxy or information statements incorporated by reference in Part III
of this Form 10-K or any amendment to this Form 10-K [X].
Based on the closing price on March 20, 1997, the aggregate market
value of voting stock held by non-affiliates of the registrant was approximately
$170,069,266.
As of the close of business on March 20, 1997, the registrant had
18,926,460 shares of common stock outstanding, of $.025 par value each.
DOCUMENTS INCORPORATED BY REFERENCE
Definitive proxy statement to be filed pursuant to Regulation 14A under
the Securities Exchange Act of 1934, incorporated by reference into Part III
hereof.
<PAGE> 2
GRAHAM-FIELD HEALTH PRODUCTS, INC.
ANNUAL REPORT ON FORM 10-K/A-3
FOR THE YEAR ENDED DECEMBER 31, 1996
PART I
ITEM 1. BUSINESS:
THE COMPANY
Graham-Field Health Products, Inc. and its wholly owned
subsidiaries (collectively, the "Company") manufacture, market and distribute
medical, surgical and a broad range of other healthcare products into the home
healthcare and medical/surgical markets through a network consisting of
approximately 18,500 customers in North America. The Company also markets and
distributes its products throughout Europe, Central and South America, and Asia.
The acquisition of Everest & Jennings International Ltd. ("Everest &
Jennings") on November 27, 1996 has positioned the Company as a leading
manufacturer of durable medical equipment in North America.
The Company's long-term strategic objective is to become the
leading provider of medical products to the rapidly growing home healthcare and
medical/surgical markets by offering the broadest product line in the industry,
single-source purchasing and technologically advanced, cost-effective delivery
systems. The cornerstone of the Company's sales and marketing strategy is the
Company's Consolidation Advantage Program ("C.A.P."). Through C.A.P., the
Company strives to become the most efficient, reliable low-cost provider of
medical products by offering its customers the ability to significantly reduce
their operating costs by consolidating the purchase of multiple product lines
through a single source. C.A.P. significantly improves the level of service to
the Company's customers by streamlining the purchasing process, decreasing order
turnaround time, reducing delivery expenses, and providing on-demand inventory.
The Company markets and distributes approximately 23,000
products under its own brand names and under suppliers' names throughout the
United States, Canada, Mexico, Europe, Central and South America, and Asia. The
Company maintains distribution and manufacturing facilities throughout the
United States, Canada, Mexico and Puerto Rico. The Company's products are
marketed to approximately 18,500 customers, principally hospital, nursing home,
physician and home healthcare dealers, healthcare product wholesalers and
retailers, including drug stores, catalog companies, pharmacies and
home-shopping related businesses. During the five years ended December 31, 1996,
the number of products offered by the Company expanded from approximately 19,000
to approximately 23,000. The expansion of the number of products offered is
primarily the result of an increase in the number of distributorship agreements
with suppliers and acquisitions of other companies and product lines.
The Company's principal products and product lines include
durable medical equipment (such as wheelchairs, homecare beds, ambulatory aids,
bathroom and safety equipment), sphygmomanometers (blood pressure measuring
devices), stethoscopes, ECG instruments, electronic thermometers, infrared heat
treatment devices, adult incontinence products,
<PAGE> 3
nutritional supplements, specialty cushions and mattresses for the treatment and
prevention of pressure sores, medicated and rubber elastic bandages, respiratory
equipment and supplies, urologicals, ostomy products, wound care products,
infection control products, first aid supplies, laboratory supplies,
antiseptics, topical anesthetics and sterile disposable medical products. By
offering a wide range of products from a single source, the Company enables its
customers to reduce their costs associated with the purchasing process,
including transaction, freight and inventory expenses. During the year ended
December 31, 1996, approximately 25% of the Company's revenues were derived from
products manufactured by the Company, approximately 18% of the Company's
revenues were derived from imported products, and approximately 57% from
products purchased from domestic sources, which includes products purchased from
Everest & Jennings prior to the acquisition. As used herein, the term "product"
means a Company stockkeeping unit.
The Company was organized under the laws of the State of
Delaware on April 6, 1981 under the name, Patient Technology, Inc. On May 27,
1988, the Company changed its name to Graham-Field Health Products, Inc. Except
where the context otherwise requires, the word "Company" as used herein includes
all of its subsidiaries. The Company's executive offices are located at 400
Rabro Drive East, Hauppauge, New York 11788 and its telephone number is (516)
582-5900.
EVEREST & JENNINGS INTERNATIONAL LTD.
Acquisition of Everest & Jennings
On November 27, 1996, the Company acquired Everest & Jennings
in a merger transaction. Through its subsidiaries, Everest & Jennings
manufactures a broad line of wheelchairs and distributes homecare beds. Everest
& Jennings' principal subsidiaries include Everest & Jennings, Inc. ("E&J")
located in Earth City, Missouri; Everest & Jennings Canadian Limited ("Everest &
Jennings Canada") located in Toronto, Canada; and Everest & Jennings de Mexico,
S.A. de C.V. ("Everest & Jennings Mexico") located in Guadalajara, Mexico. Each
of Everest & Jennings' subsidiaries manufactures wheelchairs and wheelchair
parts.
The Company believes that the combination of Everest &
Jennings' manufacturing operations with the Company's cost-effective delivery
systems and advanced technology systems will increase the Company's presence in
the home healthcare market with a greater level of service and efficiency, and a
broader portfolio of products. The coordination of the manufacturing and
distribution of the wheelchair and homecare bed product lines, which represent
the leading product lines in the home healthcare market, will enhance the
Company's position as a leading "one-stop-shop" distributor of medical products.
The Everest & Jennings name, a symbol of quality for more than 50 years, has
enabled the Company to introduce its Temco home healthcare product line and
other proprietary product lines into the rehabilitation marketplace, a virtually
untapped marketplace for the Company in the past.
-2-
<PAGE> 4
Dependence on Key Supply Contracts
Everest & Jennings' business is heavily dependent on its
maintenance of two key supply contracts. Everest & Jennings obtains the majority
of its commodity homecare wheelchairs and wheelchair components pursuant to an
exclusive supply agreement (the "Exclusive Wheelchair Supply Agreement") with
P.T. Dharma Polimetal ("P.T. Dharma"), an Indonesian manufacturer certified
under the standard quality systems of ISO 9001. The term of this agreement
extends until December 31, 1999, and on each January 1 thereafter shall be
automatically extended for one additional year unless Everest & Jennings elects
not to extend or Everest & Jennings has failed to order at least 50% of the
contractually specified minimums and the manufacturer elects to terminate. If
the Exclusive Wheelchair Supply Agreement with P.T. Dharma is terminated, there
can be no assurance that Everest & Jennings will be able to enter into a
suitable supply agreement with another manufacturer. In addition, Everest &
Jennings obtains homecare beds for distribution pursuant to a supply agreement
(the "Bed Supply Agreement") with Healthtech Products, Inc. ("Healthtech"), a
wholly-owned subsidiary of Invacare Corporation (which is a major competitor of
Everest & Jennings), which is scheduled to expire on October 15, 1997. Although
the Company is in the process of securing alternative sources of supply with
other manufacturers, there can be no assurance that arrangements as favorable as
the current supply contract will be obtainable.
Wheelchairs
Everest & Jennings develops, designs, manufactures and markets
wheelchairs into two primary categories -- rehabilitation and homecare.
The rehabilitation market is characterized by individual
needs, ongoing product innovation and government reimbursement levels.
Rehabilitation products are more sophisticated, command higher prices and
support a higher price margin structure. Most rehabilitation chairs are sold
through rehabilitation dealers working in conjunction with therapists who
prescribe the products for end users.
The homecare market is characterized by lower priced,
commodity products and includes significant institutional sales. Typically, end
users are geriatrics, those temporarily disabled or individuals with long-term
disabilities who are living at home. Funding for the homecare market is through
private insurance or state and federal programs. Everest & Jennings' homecare
chairs are sold directly through homecare dealers, as well as selected
distributors selling to hospitals and nursing homes.
Everest & Jennings develops, designs, manufactures and markets
state-of-the-art wheelchairs including ultra-lightweight wheelchairs in Everest
& Jennings' Vision product line. Everest & Jennings continues to invest in the
development of its rehabilitation wheelchair lines, both power and manual, with
primary focus on products that are well matched to user needs and reimbursement
levels and are easier to manufacture and support. During 1996, Everest &
Jennings continued to launch new products, primarily in the rehabilitation
market, as well as in
-3-
<PAGE> 5
new wheelchair market segments. Three new power wheelchairs were introduced in
1996. The new Lancer 2000 was launched mid-year as Everest & Jennings' new
flagship, power wheelchair. In addition, the Metropower was launched earlier in
the year as a lower cost alternative to the more sophisticated traditional,
power wheelchair line of Everest & Jennings. The Sabre product line of
wheelchairs, which was initially launched in 1995, was further expanded with the
addition of a lower cost model, the Sabre LTD. In the manual rehabilitation
product category, the Metro model was improved and formed the basis for several
new products using the same design architecture. The Metro LX and Metro GT were
added in 1996 to offer additional product features at slightly higher price and
reimbursement points.
The Company estimates that the aggregate domestic wheelchair
market approximates $350 million with the total North American market slightly
larger at approximately $425 million. The Company believes it has a material
share of these combined markets.
Homecare Beds
Homecare beds generally are sold to the same homecare dealer
network that purchases durable medical equipment. A patient who is discharged
from a hospital or other institution may rent a homecare bed to aid in their
recovery. Accordingly, dealers primarily retain homecare beds in a rental fleet.
In addition, Everest & Jennings offers heavy-duty, rehabilitation beds to
complement its other homecare products.
The Company estimates that the aggregate domestic market for
homecare beds is approximately $60 million. The Company believes it has a
material share of the domestic homecare bed market.
International Operations
The Canadian market is served through Everest & Jennings
Canada, while the Central and South American markets are served through Everest
& Jennings Mexico. Although Everest & Jennings in the past has not placed great
emphasis on expanding its markets beyond North America, the Company believes
that there are significant opportunities for increased growth of the Everest &
Jennings' product line in foreign markets.
Product Research and Development
Everest & Jennings continuously seeks to improve the quality,
performance and reliability of its products to meet the needs of its customer
base. Everest & Jennings has a design staff and research and development
organization located in northern California. The Everest & Jennings Design
Center is responsible for new product design for Everest & Jennings, and
conducts sponsored research and development activities.
-4-
<PAGE> 6
PRODUCTS
The Company manufactures, markets and distributes
approximately 23,000 healthcare products under its own brand names and under
suppliers' names. The Company's products are marketed to approximately 18,500
customers, principally hospital, nursing home, physician and home healthcare
dealers, healthcare product wholesalers and retailers, including drug stores,
catalog companies, pharmacies and home-shopping related businesses. For each of
the three years during the period ended December 31, 1996, substantially all of
the Company's revenues were derived from sales of products.
Product lines marketed by the Company include durable medical
equipment (such as wheelchairs, homecare beds, ambulatory aids, bathroom and
safety equipment), sphygmomano-meters (blood pressure measuring devices),
stethoscopes, ECG instruments, electronic thermometers, infrared heat treatment
devices, adult incontinence products, nutritional supplements, specialty
cushions and mattresses for the treatment and prevention of pressure sores,
medicated and rubber elastic bandages, respiratory equipment and supplies,
urologicals, ostomy products, wound care products, infection control products,
first aid supplies, laboratory supplies, antiseptics, topical anesthetics and
sterile disposable medical products.
Sales of the Company's line of sphygmomanometers accounted for
7%, 11% and 14% of the Company's annual revenues during the years ended December
31, 1996, 1995 and 1994, respectively. The Company's lines of incontinence
products; wound care and ostomy products; bathroom safety equipment;
wheelchairs; and ambulatory aids accounted for approximately 8%, 7%, 6%, 6% and
5%, respectively, of the Company's annual revenues in 1996. No other product
line or product accounted for more than 5% of annual revenues. Approximately 4%
of all products offered by the Company during each of the years ended December
31, 1996, 1995 and 1994, respectively, accounted for approximately 80% of annual
revenues in each such year. The number of products marketed by the Company
increased from approximately 19,000 in 1991 to approximately 23,000 in 1996.
SALES AND MARKETING
The Company markets its products to approximately 18,500
customers, principally medical/surgical supply dealers and home healthcare
retailers and wholesalers, which include drug store chains and home-shopping
related businesses. The Company's products are marketed and distributed
throughout the United States, Canada, Mexico, Europe, Central and South America
and Asia. The Company's North American distribution network includes primary
points of distribution located in Hauppauge, New York; St. Louis, Missouri;
Jacksonville, Florida; Santa Fe Springs, California; Toronto, Canada; and
Guadalajara, Mexico. Secondary points of distribution include Graham-Field
Express satellite facilities located in Mount Vernon, New York; Dallas, Texas;
and San Juan, Puerto Rico.
The Company's automated "paperless" warehouse and distribution
center located in St. Louis, Missouri (the "St. Louis Facility") is a
"state-of-the-art" facility designed by IBM. The St. Louis Facility incorporates
sophisticated software and hardware technologies, and
-5-
<PAGE> 7
provides for the highest quality levels of customer service, delivery cycles,
inventory turnover and distribution efficiency within the medical products
industry. The St. Louis Facility ranks as one of the most technologically
advanced distribution centers in the industry.
Graham-Field Express
The Company provides "same-day" and "next-day" service to home
healthcare dealers of strategic home healthcare products, including Temco
patient aids, adult incontinence products, Everest & Jennings wheelchairs, Smith
& Davis homecare beds, nutritional supplements, and other freight intensive and
time sensitive products through its satellite Graham-Field Express facilities.
On March 7, 1996, the Company introduced its innovative Graham-Field Express
program in the metropolitan New York area, which provides one of the most
personalized service alternatives in the healthcare industry. Graham-Field
Express enables customers to reduce inventory costs and eliminate warehousing
and other costs associated with the purchasing process. The Graham-Field
Express program differs from Graham-Field's standard distribution model in that
the Graham-Field Express program focuses on same-day and next-day services to
home healthcare dealers of a limited number of strategic home healthcare
products. On September 5, 1996, the Company opened its second Graham-Field
Express facility through its acquisition of V.C. Medical Distributors Inc.
("V.C. Medical"), a wholesale distributor of medical products located in Puerto
Rico, which currently operates as Graham-Field Express (Puerto Rico). On January
29, 1997, the Company opened its third Graham-Field Express facility in Dallas,
Texas, which currently operates as Graham-Field Express (Dallas). Graham-Field
Express supplements the Company's vast distribution network, enabling the
Company to compete more aggressively in the home healthcare market. The Company
plans to open an additional three (3) to four (4) Graham-Field Express sites in
1997 and eight (8) in 1998. A new Graham-Field Express location is scheduled to
open in Baltimore, Maryland in April 1997. By late 1999, the Company plans to
have a total of approximately twenty-five (25) Graham-Field Express locations
serving all of the major U.S. markets.
Drop-Ship Programs
The Company has developed a seamless distribution program to
enable orders to be shipped from Graham-Field's distribution facilities to end
users on behalf of its customers. The Company's customers realize significant
benefits from the Company's drop-ship program by significantly reducing their
operating costs by eliminating the receiving and shipping process and inventory
carrying costs, while reducing the product delivery time to end-users.
Initially, the program will operate from the Company's St. Louis Facility. The
Company plans to expand the drop-ship program to cover all major U.S. markets.
Sales and Marketing
The Company's sales force presents its C.A.P. program to
customers as a means of reducing their operating costs associated with the
purchasing process by consolidating purchases of multiple products through a
single supplier - the Company. Other benefits realized under C.A.P. include
decreased order turnaround time, reduced delivery expenses associated with
-6-
<PAGE> 8
the consolidation of purchase orders, on-demand inventory for customers, which
reduce customer warehousing costs, and reduced administrative costs and expenses
through the streamlining of the purchasing process. The Company's sales
representatives meet with customers to analyze individual customer's needs and
to demonstrate cost reducing opportunities made possible by the C.A.P. program.
The Company's domestic sales and marketing strategies are
developed on a market-by-market basis through two primary business units:
Medical/Surgical and Home Healthcare. While the Company's sales and marketing
strategies are developed and conducted on a business unit basis, the sale of the
Company's products overlap all business units.
The Medical/Surgical business unit customer base consists of
medical/surgical supply dealers who service hospitals, nursing homes, acute care
facilities, out-patient surgi-centers, physicians and other healthcare
facilities. The Home Healthcare business unit customer base includes durable
medical equipment suppliers, home healthcare equipment suppliers, respiratory
supply dealers, specialty retailers, independent pharmacies, and catalog
companies. The Home Healthcare business unit markets the Company's consumer
products to retailers who distribute products to the consumer market, including
drug store chains, mass merchandisers, department stores and home-shopping
related businesses. In general, the dealers, wholesalers and retailers to whom
the Company markets its products also sell other medical products, some of which
compete with the Company's products.
The Company's sales and marketing sales force is directed by a
sales management team consisting of an Executive Vice President of Sales and
Marketing, a Vice President of the Medical/Surgical business unit, a Vice
President of the Home Healthcare business unit, a Vice President of Sales of
Everest & Jennings, a Vice President of International Sales, and a President of
Graham-Field (Canada), a newly-formed division of Everest & Jennings Canada. The
Vice Presidents of the Home Healthcare and Medical/Surgical business units
direct the sales and marketing strategy of the business units and oversee the
Company's five (5) regional sales Vice Presidents.
The international group consists of several in-house sales
employees, as well as one representative in Taiwan. The Company's Canadian sales
and marketing activities are directed by the President of Graham-Field (Canada),
who oversees three (3) regional sales managers, fourteen (14) direct, full-time
sales employees and two (2) independent manufacturers representatives.
The Company's five (5) regional sales Vice Presidents oversee
the day-to-day operations of the domestic sales force. The domestic sales force
consists of approximately fifteen (15) direct, full-time sales employees and
fifty (50) independent manufacturers representatives. The Company's specialty
rehabilitation sales force, consisting of approximately forty (40) sales
persons, is directed by the Vice President of Sales of Everest & Jennings.
Everest & Jennings' specialty rehabilitation sales force conducts training
activities for the benefit of dealers and their
-7-
<PAGE> 9
personnel, physical and occupational therapists, and other healthcare
professionals and reimbursement agencies. This training is primarily concerned
with the features and benefits of Everest & Jennings' rehabilitation products,
and the training also covers the proper fitting and use of wheelchairs and
related equipment. The full-time sales employees receive both salary and
commission, while the independent manufacturers representatives work solely on
commission.
During 1995, the Company introduced a new corporate campaign
to clarify and strengthen the Company's identity, and increase the market
presence of its proprietary product lines. As part of the campaign, the Company
developed a new packaging theme and catalog, which the Company believes offers
its customers the largest selection of healthcare products available from a
single catalog. The "Sundry Times", the Company's monthly direct brochure,
regarded by customers as one of the most useful purchasing tools in the
industry, was redesigned and improved. The Company has also introduced an
aggressive print advertising campaign with both product and image ads designed
to support the new corporate image. In addition, the Company has introduced new
product brochures, an extensive library of product line video tapes, cooperative
advertising programs, and sales promotions to reinforce the Company's on-going
commitment to satisfy the needs of its customers. A CD-ROM version of the
Company's catalog and an Internet interactive website are in the process of
being developed.
CUSTOMERS
The Company's products are marketed to principally hospital,
nursing home, physician and home healthcare dealers, healthcare product
wholesalers and retailers, including drug stores, catalog companies, pharmacies
and home shopping related businesses. No single customer or buying group
accounted for more than 10% of the Company's revenues in 1996.
The Company's Medical/Surgical business unit markets and sells
its products to approximately 4,000 medical and surgical supply dealers. The
Company believes that it sells to all significant medical and surgical supply
dealers. The dealers in turn sell the Company's products principally to
physicians, hospitals, nursing homes and other healthcare facilities.
The Home Healthcare business unit markets and sells its
products to approximately 14,500 customers which consist of durable medical
equipment suppliers, home healthcare equipment suppliers, respiratory supply
dealers, specialty retailers and independent pharmacies. The Company believes
that it transacts business with substantially all of the significant home
healthcare dealers in the United States. The Home Healthcare business unit also
markets and sells its products to the consumer market consisting of drug store
chains, mass merchandisers, department stores, and home shopping related
businesses. Consumers who purchase from such customers of the Company usually do
so upon the advice of physicians, hospital discharge planners, nurses or other
professionals.
PRODUCT SOURCES
-8-
<PAGE> 10
During the year ended December 31, 1996, approximately 25% of
the Company's revenues were derived from products manufactured by the Company,
approximately 18% of the Company's revenues were derived from imported products,
and approximately 57% from products purchased from domestic sources, which
includes products purchased from Everest & Jennings prior to the acquisition.
The Company is heavily dependent on its maintenance of two key
supply contracts. Everest & Jennings obtains the majority of its homecare
wheelchairs and wheelchair components under the Exclusive Wheelchair Supply
Agreement with P.T. Dharma Polimetal. If the Exclusive Wheelchair Supply
Agreement with P.T. Dharma is terminated, there can be no assurance that Everest
& Jennings will be able to enter into a suitable supply agreement with another
manufacturer. In addition, Everest & Jennings obtains homecare beds for
distribution pursuant to the Bed Supply Agreement with Healthtech, which is
scheduled to expire on October 15, 1997. Although the Company is in the process
of securing alternative sources of supply with other manufacturers, there can be
no assurance that arrangements as favorable as the current supply agreement will
be obtainable.
The Company purchases products from approximately 1,200
domestic and foreign suppliers. The Company has entered into exclusive and
non-exclusive distribution agreements with a number of its domestic and foreign
suppliers. Under such agreements, suppliers may designate the markets into which
the Company can sell the products and may stipulate minimum annual sales volumes
which are to be achieved by the Company. Most of the distribution agreements are
cancelable by either party upon one to six months' notice. The Company does not
believe that cancellation of any such agreements would have a material adverse
effect on the Company, because comparable products are obtainable from
alternative sources upon acceptable terms.
The Company currently purchases a substantial portion of its
sphygmomanometers and stethoscopes from a limited number of suppliers in the Far
East. In addition, the Company sources component parts for sphygmomanometers and
stethoscopes and assembles such products in its facility located in Hauppauge,
New York.
Principal products produced by the Company are EVEREST &
JENNINGS(R) wheelchairs, SMITH & DAVIS(R) homecare beds, LABTRON(R) stethoscopes
and blood pressure instruments, JOHN BUNN(R) respiratory aid products,
MEDICOPASTE(R) medicated bandages, rubber elastic bandages, SURVALENT(R)
electronic thermometry systems, silver nitrate applicators, examination lamps
and sterile packages under the MSP(R) label, GRAFCO(R) medical supplies,
including silver nitrate applicators and examination lamps, the TEMCO(R) product
line of patient aids, bathroom safety equipment and patient room equipment, and
Aquatherm specialty cushions and mattresses for the treatment and prevention of
pressure sores.
-9-
<PAGE> 11
PATENTS AND TRADEMARKS
The Company believes that its business is dependent in part on
its ability to establish and maintain patent protection for its proprietary
technologies, products and processes, and the preservation of its trade secrets.
The Company currently holds a number of United States patents relating to the
EVEREST & JENNINGS(R) and TEMCO(R) product lines. In addition, the Company holds
certain international patents relating to the components of its SURVALENT(R)
electronic thermometry system. Other companies may provide similar products
which may not be covered by the Company's issued patents. The Company must
operate without infringing upon the proprietary rights of other parties. There
can be no assurance that any United States or international patents issued or
licensed to the Company will not be successfully challenged, invalidated or
circumvented, or that patents will be issued in respect of patent applications
to which the Company currently holds rights. In addition, the Company
distributes certain patented products pursuant to licensing arrangements. In the
event a licensing arrangement is terminated, the Company may not be able to
continue to distribute the patented product. The Company believes that any such
termination will not have a material adverse effect on the business of the
Company, because products comparable to those currently distributed under such
licensing arrangements are obtainable from other sources upon acceptable terms.
The Company has registered a significant number of trademarks
in the United States, including, but not limited to, "GRAHAM-FIELD," "EVEREST &
JENNINGS," "SMITH & DAVIS," "JOHN BUNN," "BRISTOLINE," "SURVALENT," "MEDICOPASTE
BANDAGE," "HEALTHTEAM," "LABTRON," "GRAFCO," "TEMCO" and "TENDERCLOUD."
PRODUCT LIABILITY
Although the Company maintains product liability insurance,
there can be no assurance that such coverage will be adequate to protect the
Company from liabilities it may incur. Product liability insurance is expensive
and there can be no assurance that the Company will be able to continue to
obtain and maintain insurance at acceptable rates. Potential losses from any
possible future liability claims and the effect which product liability
litigation may have on the reputation and marketability of the Company's
products could have a material adverse effect on the Company's business and
financial condition.
GOVERNMENT REGULATION
The healthcare industry is affected by extensive government
regulation and funding at the federal and state levels. Changes in regulations
and healthcare policy occur frequently and may impact the size, and the growth
potential of the Company, and the profitability of products sold by the Company
in each market. Although the Company is not a direct provider under Medicare and
Medicaid, the Company's products are sold to its customers, many of which are
providers under these programs and which depend upon Medicare and/or Medicaid
reimbursement for a portion of their revenue. Changes in Medicare and Medicaid
regulations may adversely
-10-
<PAGE> 12
impact the Company's revenues and collections indirectly by reducing the
reimbursement rate received by the Company's customers. The reduction in
reimbursement rates will place downward pressure on prices charged for the
Company's products sold to customers subject to Medicare and Medicaid
reimbursement programs. The Company believes that its C.A.P. program will enable
customers to respond to the reduction in reimbursement rates by consolidating
the purchase of multiple product lines through a single supplier - the Company.
The Federal Food, Drug and Cosmetic Act, the Safe Medical
Devices Act and regulations issued or proposed thereunder, provide for
regulation by the Federal Food and Drug Administration ("FDA") of the marketing,
manufacturing, labeling, packaging and distribution of medical devices and
drugs, including the Company's products. Among these regulations are
requirements that medical device manufacturers register with the FDA, list
devices manufactured by them and file various kinds of reports. The FDA's "Good
Manufacturing Practice for Medical Devices" regulation sets forth requirements
for, among other things, the Company's manufacturing process and associated
record creation and maintenance, including tests and sterility.
The Company uses the services of an unaffiliated outside firm
to sterilize its GRAFCO(R) tampons and MSP(R) product line and tests of
sterility are conducted by an unaffiliated laboratory. Records of sterilization
and related tests are kept by the Company. The Company has also engaged the
services of an outside consulting firm to monitor the quality control program in
force to ensure that all manufactured products and supplier products comply with
FDA requirements. The Company's outside consultants are in the process of
implementing ISO 9001 certification on a company-wide basis, which will enhance
the Company's overall standard quality systems, and enable the Company to comply
with European regulatory requirements.
Unscheduled FDA inspections of the Company's facilities may
occur from time to time to determine compliance with FDA regulations. Certain
requirements must be met prior to the initial marketing of medical devices.
These range from a minimum obligation of waiting to receive a determination of
substantial equivalence from the FDA before the introduction of a medical device
which the Company has determined is substantially similar to devices already on
the market, to a maximum obligation of complying with the potentially expensive
and time-consuming testing process necessary to obtain FDA approval prior to the
commercial marketing of new medical devices. In addition, the FDA has the
authority to issue performance standards for devices manufactured by the
Company. Should such standards be issued, the Company's products would be
required to conform to them.
To date, the Company has not experienced any significant
difficulty or expense in complying with the requirements imposed on it by the
FDA or other government agencies. The Company believes that the manufacturing
and quality control procedures it employs conform to requirements of the "Good
Manufacturing Practice for Medical Devices" regulation and does not anticipate
having to make any material expenditures as a result of these requirements.
-11-
<PAGE> 13
COMPETITION
The Company competes with many other manufacturers and
distributors who offer one or more products competitive with the Company's
products; however, the Company believes that no single competitor serving the
Company's markets offers as broad a product range as the Company. The Company's
principal means of competition are the breadth of its product range, quality,
price and speed of delivery. The C.A.P. program enables the Company to compete
by offering customers reduced operating costs associated with purchasing by
consolidating purchases of multiple products. With respect to the Company's
Everest & Jennings wheelchairs and Smith & Davis homecare beds, the Company's
primary competitors include Invacare Corporation, Sunrise Medical Corporation
and Fuqua Enterprises. Competition for the sale of wheelchairs and homecare beds
is intense and is based on a number of factors, including quality, reliability,
price, financing programs, delivery and service. The Company believes that the
quality, reputation and recent technological advances relating to its Everest &
Jennings wheelchairs and Smith & Davis homecare beds are favorable factors in
competing with other manufacturers. Many of the Company's competitors have
substantially greater financial and other resources than the Company.
EMPLOYEES
As of March 8, 1997, the Company had 1,421 employees of which
seven were executive officers, 268 were administrative and clerical personnel
(of which 12 were part-time employees), 204 were sales, marketing and customer
service personnel (of which four were part-time employees) and 942 were
manufacturing and warehousing personnel (of which 43 were part-time employees).
The Company is a party to five (5) collective bargaining
agreements covering the Company's facilities located in Hauppauge, New York;
Passaic, New Jersey; Earth City, Missouri; Ontario, Canada; and Guadalajara,
Mexico. The collective bargaining agreements cover approximately 620 employees.
The collective bargaining agreements for Hauppauge, New York; Passaic, New
Jersey; Earth City, Missouri; Ontario, Canada; and Guadalajara, Mexico are
scheduled to expire on September 30, 1997, July 27, 1999, September 13, 1999,
July 24, 1998 and December 31, 1997, respectively.
The Company has never experienced an interruption or
curtailment of operations due to labor controversy, except for a three-day
period during the summer of 1993 in which the Company experienced a strike at
its Passaic, New Jersey facility, which did not have a material adverse effect
on the Company's operations. The Company considers its employee relations to be
satisfactory.
-12-
<PAGE> 14
BUSINESS COMBINATIONS
The Company has had an active acquisition program from its
inception, and has completed 14 acquisitions since 1981. The Company focuses on
acquisitions which enable the Company to increase its market share, expand its
existing product lines, consolidate manufacturing and distribution facilities,
and enable the Company to enter into new markets and complement the Company's
existing business. Among other acquisitions, in 1983 the Company acquired
Labtron, Inc. and in 1985 it acquired Graham-Field, Inc., both of which form the
core of the Company's current business.
On May 31, 1991, the Company acquired 90% of the outstanding
stock of Horizon International Health Care, Inc., formerly known as AquaTherm
Products Corporation ("Aquatherm"), a manufacturer and distributor of
deodorizers and pressure control products for the treatment or prevention of
decubitus ulcers (pressure sores). On June 11, 1991, the Company acquired the
remaining 10% of the outstanding stock of Aquatherm. The total cash purchase
price for the outstanding stock of Aquatherm was $2,356,000.
On October 1, 1991, the Company acquired from TEMCO National
Corp. ("TEMCO") substantially all of the operating assets (excluding the real
estate) of the TEMCO Healthcare Division for a purchase price consisting of
$5,849,000 in cash which is net of certain purchase price adjustments. In
connection with the acquisition, the Company assumed certain liabilities and
entered into a fifteen year lease for TEMCO's manufacturing and warehouse
facility located in Passaic, New Jersey. See "Properties". The operating assets
acquired by the Company included substantially all of the assets (excluding the
real estate) used by TEMCO in the business of manufacturing and marketing
medical supply products, including ambulatory aids, bath and shower accessories,
geriatric seating units and patient room assistance and convenience accessories.
On April 27, 1992, the Company acquired certain assets of
ConvaTec, a division of E.R. Squibb & Sons, Inc. ("Bandage"), for a purchase
price of $369,000 in cash. In connection with the acquisition, the Company
assumed certain liabilities of Bandage, and entered into a long-term lease for
Bandage's manufacturing facility located in Central Falls, Rhode Island. See
"Properties." The assets acquired by the Company included substantially all of
the assets used by Bandage in the business of manufacturing elastic bandages.
On May 28, 1992, the Company acquired substantially all of the
operating assets of Diamond Medical Equipment Corp. ("DEC") and National Health
Care Equipment Inc. ("NHC") for a purchase price of $9,306,000 in cash, and the
issuance and delivery to the principal stockholders of DEC and NHC of 210,176
shares of common stock of the Company. In addition, the Company repaid certain
bank indebtedness of DEC and NHC in the amount of $3,200,000 and assumed certain
liabilities of DEC and NHC. DEC and NHC, formerly privately-owned companies, are
manufacturers of patient aids and distributors of adult incontinence products,
nutritional supplements and other home healthcare products.
-13-
<PAGE> 15
Effective July 1, 1995, the Company acquired substantially all
of the assets and liabilities of National Medical Excess Corp., a distributor of
used and refurbished medical products, including respiratory and durable medical
equipment. The purchase price, including acquisition expenses, was approximately
$723,000 in cash, plus the assumption of certain liabilities.
On March 4, 1996, the Company sold its Gentle Expressions
breast pump product line to The Lumiscope Company, Inc. for a purchase price of
$1,000,000, of which $500,000 was paid in cash with the balance in a secured
subordinated promissory note in the aggregate principal amount of $500,000,
payable over 48 months with interest at the prime rate of interest plus 1%.
On September 4, 1996, the Company acquired substantially all
of the assets of V.C. Medical for a purchase price consisting of $1,703,829 in
cash, and the issuance of 32,787 shares of common stock of the Company, valued
at $7.625 per share representing the closing market price of the common stock of
the Company on the last trading day immediately prior to the closing. In
addition, the Company assumed certain liabilities of V.C. Medical in the amount
of $296,721. Under the terms of the transaction, in the event the pre-tax income
of the acquired business equals or exceeds $1,000,000 during the twelve (12)
months following the closing date, an additional $500,000 in cash will be paid
to V.C. Medical. The shares were delivered into escrow, and will be held in
escrow until February 4, 1998, subject to any claims for indemnification or
purchase price adjustments in favor of the Company.
On November 27, 1996, the Company acquired Everest & Jennings
in a merger transaction. In the merger, each share of the common stock of
Everest & Jennings, other than shares of the common stock of Everest & Jennings
cancelled pursuant to the merger, was converted into the right to receive .35
shares of the common stock of the Company. In connection with the merger,
2,522,691 shares of common stock of the Company were issued in exchange for the
common stock of Everest & Jennings. The Company's common stock was valued at
$7.64 per share, which represented the average closing market price of the
Company's common stock for the period three business days immediately prior to
and three business days immediately after the announcement of the execution of
the merger agreement. In addition, in connection with, and at the effective time
of the merger:
(i) BIL (Far East Holdings) Limited, a Hong Kong
corporation and the majority stockholder of Everest &
Jennings ("BIL"), was issued 1,922,242 shares of
common stock of the Company in consideration of the
repayment of indebtedness owing by Everest & Jennings
in the amount of $24,989,151 to Hong Kong and
Shanghai Banking Corporation Limited, which
indebtedness (the "HSBC Indebtedness") was guaranteed
by BIL. The proceeds of such stock purchase were
contributed by the Company to Everest & Jennings
immediately following the merger and used to
discharge the HSBC Indebtedness.
-14-
<PAGE> 16
(ii) The Company issued $61 million stated value of a new
Series B Cumulative Convertible Preferred Stock (the
"Series B Preferred Stock") to BIL in exchange for
certain indebtedness of Everest & Jennings owing to
BIL and shares of E&J preferred stock owned by BIL.
The Series B Preferred Stock is entitled to a
dividend of 1.5% per annum payable quarterly, votes
on an as-converted basis as a single class with the
common stock of the Company and the Series C
Preferred Stock (as defined below), is not subject to
redemption and is convertible into shares of the
common stock of the Company (x) at the option of the
holder thereof, at a conversion price of $20 per
share (or, in the case of certain dividend payment
defaults, at a conversion price of $15.50 per share),
(y) at the option of the Company, at a conversion
price equal to current trading prices (subject to a
minimum conversion price of $15.50 and a maximum
conversion price of $20 per share) and (z)
automatically on the fifth anniversary of the date of
issuance at a conversion price of $15.50 per share.
Such conversion prices are subject to customary
antidilution adjustments. Based on an independent
valuation, the fair value ascribed to the Series B
Preferred Stock was $28,200,000.
(iii) BIL was issued $10 million stated value of a new
Series C Cumulative Convertible Preferred Stock (the
"Series C Preferred Stock"), the proceeds of which
are available to the Company for general corporate
purposes. The Series C Preferred Stock is entitled to
a dividend of 1.5% per annum payable quarterly, votes
on an as-converted basis as a single class with the
common stock of Company and the Series B Preferred
Stock, is subject to redemption as a whole at the
option of the Company on the fifth anniversary of the
date of issuance at stated value and, if not so
redeemed, will be convertible into shares of the
common stock of the Company automatically on the
fifth anniversary of the date of issuance at a
conversion price of $20 per share, subject to
customary antidilution adjustments. Based on an
independent valuation, the fair value ascribed to the
Series C Preferred Stock was $3,400,000.
(iv) Certain indebtedness in the amount of $4 million
owing by the Company to BIL was exchanged for an
equal amount of unsecured subordinated indebtedness
of the Company maturing on April 1, 2001 and bearing
interest at the effective rate of 7.7% per annum.
On February 28, 1997, Everest & Jennings Canada acquired
substantially all of the assets and certain liabilities of Motion 2000 Inc.
("Motion 2000") and its wholly-owned subsidiary, Motion 2000 Quebec Inc.
("Motion Quebec"), for a purchase price equal to Cdn. $2.9 million (Canadian
dollars), or approximately $2.15 million in U.S. dollars. The purchase price was
paid by the issuance of 187,733 shares of the common stock of the Company valued
at $11.437 per share, of which 28,095 shares were delivered into escrow. The
purchase price is subject to adjustment if the final determination of the
closing date net book value of the assets
-15-
<PAGE> 17
acquired by Everest & Jennings Canada is equal to or less than Cdn. $450,000
(Canadian dollars), or approximately $333,000 in U.S. dollars. All of the
escrowed shares will be held in escrow until the earlier to occur (the "Initial
Release Date") of June 28, 1997, or the final resolution of the purchase price.
On the Initial Release Date, a portion of the escrowed shares will be released
in an amount equal to the difference between (i) 28,095 shares and (ii) the sum
of the number of (x) any escrowed shares subject to any indemnification claims,
(y) any escrowed shares used to satisfy any adjustment to the purchase price,
and (z) 18,729 shares. The balance of the escrowed shares will be released on
December 31, 1997, subject to any claims for indemnification.
On March 7, 1997, E&J acquired Kuschall of America, Inc.
("Kuschall"), a manufacturer of pediatric wheelchairs, high-performance adult
wheelchairs and other rehabilitation products, for a purchase price of
$1,510,000, representing the net book value of Kuschall. The purchase price was
paid by the issuance of 116,154 shares of the common stock of the Company valued
at $13.00 per share, of which 23,230 shares were delivered into escrow. The
escrow shares will be released on March 7, 1999, subject to any purchase price
adjustments in favor of the Company and claims for indemnification.
On August 28, 1997, the Company acquired all of the issued and
outstanding shares of the capital stock of Medical Supplies of America, Inc., a
Florida corporation ("Medapex"), pursuant to an Agreement and Plan of
Reorganization (the "Reorganization Agreement") dated August 28, 1997, by and
among the Company, S.E. (Gene) Davis and Vicki Ray (collectively the "Medapex
Selling Stockholders"). In accordance with the terms of the Reorganization
Agreement, Medapex became a wholly-owned subsidiary of the Company and the
Medapex Selling Stockholders received in the aggregate 960,000 shares of Company
Common Stock in exchange for all of the issued and outstanding shares of the
capital stock of Medapex. Pursuant to a Real Estate Sales Agreement dated as of
August 28, 1997 (the "Real Estate Sales Agreement") by and between the Company
and BBD&M, a Georgia Limited Partnership and an affiliate of Medapex, the
Company acquired Medapex's principal corporate headquarters and distribution
facility in Atlanta, Georgia for a purchase price consisting of (i) $622,335
payable (x) by the issuance of 23,156 shares of common stock of the Company and
(y) in cash in the amount of $311,167, and (ii) the assumption of debt of the
Company in the amount of $477,664. In connection with the transaction, the
Company also entered into a Registration Rights Agreement dated as of August 28,
1997, pursuant to which the Company agreed to register for resale the shares of
common stock of the Company issued pursuant to the Reorganization Agreement and
the Real Estate Sales Agreement. Each of the Medapex Selling Stockholders
entered into a two-year employment agreement and non-competition agreement with
the Company. The acquisition of Medapex qualifies as a tax-free reorganization
and was accounted for as a "pooling of interests." Accordingly, the Company's
financial statements for periods prior to the combination have been restated to
include the results of Medapex for all periods.
There can be no assurance that any additional acquisitions
will be effected.
-16-
<PAGE> 18
ITEM 2. PROPERTIES:
The Company's principal executive offices are located in
Hauppauge, New York.
The Company's primary domestic distribution centers are
located in Hauppauge, New York; St. Louis, Missouri; Santa Fe Springs,
California; and Jacksonville, Florida. Additional points of distribution
include Graham-Field satellite locations in Mount Vernon, New York; Dallas,
Texas; and San Juan, Puerto Rico. The Company's primary manufacturing
facilities are located in Passaic, New Jersey; Earth City, Missouri; Clay
Falls, Rhode Island; Guadalajara, Mexico; and Toronto, Canada. The
manufacturing facilities located in Toronto, Canada and Guadalajara,
Mexico are owned by the Company. The Company plans to open a new leased
facility in Baltimore, Maryland in April 1997, which will operate as a
Graham-Field Express satellite location.
The Company believes that its facilities are in good repair
and provide adequate capacity for the near term growth of the Company's
business.
-17-
<PAGE> 19
Existing leases for the Company's principal facilities are summarized in the
following table.
A. Manufacturing Facilities:
<TABLE>
<CAPTION>
Lease
Approx. Expiration
Location Sq. Ft. Date Principal Use Annual Rent
-------- ------- ---- ------------- -----------
<S> <C> <C> <C> <C>
400 Rabro Drive East 105,000 12/31/06 Corporate Office, $ 934,000 1/01/96 - 12/31/01
Hauppauge, NY Manufacturing, 1,023,000 1/01/02 - 12/31/06
Distribution
3601 Rider Trail 147,000 7/31/02 Manufacturing, $ 279,300 1/01/96 - 7/31/97
Earth City, MO Distribution 323,400 8/01/97 - 7/31/02
125 South Street 120,000 12/31/04 Manufacturing, $ 336,000 1/01/96 - 12/31/99
Passaic, NJ Distribution 360,000 1/01/00 - 12/31/04
131 Clay Street 21,467 12/31/97 Manufacturing, $ 67,555 1/01/96 - 12/31/97
Central Falls, RI Distribution
</TABLE>
B. Distribution Facilities:
<TABLE>
<CAPTION>
Lease
Approx. Expiration
Location Sq. Ft. Date Principal Use Annual Rent
-------- ------- ---- ------------- -----------
<S> <C> <C> <C> <C>
12055 Missouri 144,000 3/31/07 Warehouse, $ 504,300 1/01/96 - 3/31/97
Bottom Road(1) Distribution 561,950 4/01/97 - 3/31/02
St. Louis County, MO 648,400 4/01/02 - 3/31/07
11954 East Washington Blvd 52,810 2/01/02 Warehouse, $ 228,144 2/01/97 - 8/01/99
Santa Fe Springs, CA Distribution 250,956 9/01/99 - 2/01/02
8291 Forshee Drive 28,255 8/31/99 Warehouse, $ 112,185 7/01/96 - 8/31/99
Jacksonville, FL Distribution
144 East Kingsbridge 48,000 2/28/99 Warehouse, $ 162,000 3/01/96 - 2/28/97
Mount Vernon, NY Distribution 180,000 3/01/97 - 2/28/99
Puerto Rico Highway #1 21,600 10/08/99 Warehouse, $ 114,000 10/08/96 - 10/08/99
Rio Canas Ward Distribution
Caguas, PR
135 Fell Court 30,000 12/31/06 Warehouse $ 202,500 1/01/96 - 12/31/96
Hauppauge, NY 222,750 1/01/97 - 12/31/01
240,000 1/01/02 - 12/31/06
7447 New Ridge Road 20,147 4/30/02 Warehouse, $ 90,660 4/15/97 - 4/30/99
Hanover, MD Distribution 95,700 5/01/99 - 4/30/02
1707 Falcon Drive 10,151 7/31/01 Warehouse, $ 35,520 8/01/96 - 7/31/99
DeSoto, TX Distribution 38,040 8/01/99 - 7/31/00
40,080 8/01/00 - 7/31/01
</TABLE>
(1) The lease payments for the St. Louis Facility for the period April 1,
1997 through March 31, 2007 are subject to fluctuations in the consumer
price index. In no event shall the base rent exceed the amounts
reflected in the table.
-18-
<PAGE> 20
ITEM 3. LEGAL PROCEEDINGS:
On June 19, 1996, a class action lawsuit was filed on behalf of all
stockholders of Everest & Jennings (other than the named defendants) in the
Delaware Court of Chancery, following announcement on June 17, 1996 of the
original agreement in principle between Everest & Jennings and the Company. The
class action names as defendants the Company, Everest & Jennings, Everest &
Jennings' directors, and BIL. The class action challenges the transactions
contemplated by the original agreement in principle, alleging, among other
things, that (i) such transactions were an attempt to eliminate the public
stockholders of Everest & Jennings at an unfair price, (ii) BIL will receive
more value for its holdings in Everest & Jennings than its minority
stockholders, (iii) the public stockholders will not be adequately compensated
for the potential earnings of Everest & Jennings, (iv) BIL and the directors of
Everest & Jennings breached or aided and abetted the breach of fiduciary duties
owed to the stockholders (other than the defendants) by not exercising
independent business judgment and having conflicts of interest, and (v) the
Company aided and abetted and induced breaches of fiduciary duties by other
defendants by offering incentives to members of management, either in the form
of continued employment or monetary compensation and perquisites, in exchange
for their approval of the merger. The class action seeks to rescind the merger
or an award of rescissionary damages if it cannot be set aside, and also prays
for an award of compensatory damages. The Company intends to vigorously defend
the lawsuit and does not believe that the outcome of the lawsuit will have a
material adverse effect on the Company's consolidated financial condition or
results of operations.
On May 21, 1996, the Company was sued by Minnesota Mining &
Manufacturing Company ("3M") in a claim purportedly arising under federal, state
and common law trademark, false advertising, and unfair competition laws, as
well as for breach of, and interference with, contracts. 3M alleges that the
Company is selling 3M products in violation of federal and state law, and seeks
monetary damages in an unspecified amount, as well as injunctive relief against
the Company's continued sale of 3M products. The claim was filed in the Southern
District of New York. The Company vigorously denies the allegations of 3M's
complaint, and has filed an answer denying the allegations of wrongdoing and
asserting affirmative defenses. In addition, the Company has asserted
counterclaims against 3M under federal antitrust laws, as well as an unfair
competition claim. On October 16, 1996, 3M moved to dismiss the Company's
antitrust counterclaims. Briefing of the motion has been completed and the
parties are awaiting a decision. 3M has proposed a settlement of all claims
pursuant to which the Company would, among other things, agree to restrict its
purchases of 3M products to certain authorized 3M dealers, and make a payment of
no more than $400,000. Although settlement discussions are ongoing, it is not
possible to predict the outcome of such discussions.
Everest & Jennings and its subsidiaries are parties to certain lawsuits
and proceedings as described below (the "Everest & Jennings Proceedings"). Under
the terms of the Amended and Restated Stockholder Agreement dated as of
September 3, 1996, as amended on
-19-
<PAGE> 21
September 19, 1996, by and among BIL, the Company and Irwin Selinger (the
"Stockholder Agreement"), BIL has agreed to indemnify the Company and its
subsidiaries against the Everest & Jennings Proceedings in the event the amount
of losses, claims, demands, liabilities, damages and all related costs and
expenses (including attorneys' fees and disbursements) in respect of the Everest
& Jennings Proceedings exceeds in the aggregate the applicable amounts reserved
for such proceedings on the books and records of Everest & Jennings as of
September 3, 1996. In view of BIL's obligation to indemnify the Company and its
subsidiaries with respect to such proceedings, management does not expect that
the ultimate liabilities, if any, with respect to such proceedings, will have a
material adverse effect on the consolidated financial position or results of
operations of the Company.
On July 17, 1990, a class action suit was filed in the United States
District Court for the Central District of California by a stockholder of
Everest & Jennings against Everest & Jennings and certain of its present and
former directors and officers. The suit seeks unspecified damages for alleged
non-disclosure and misrepresentation concerning Everest & Jennings in violation
of federal securities laws. The district court dismissed the complaint on March
26, 1991, and plaintiff filed his first amended complaint on May 8, 1991. The
district court again granted a motion to dismiss the entire action on November
26, 1991. Plaintiff then took an appeal to the Ninth Circuit, which reversed the
district court's dismissal of the first amended complaint and remanded the case
to the district court for further proceedings. On March 25, 1996, the district
court granted Plaintiff's motion to certify a class composed of purchasers of
the Everest & Jennings' common stock during the period from March 31, 1989 to
June 12, 1990. Plaintiff's counsel has not as yet submitted to the court any
proposed notice of class certification and, consequently, the members of the
class have not been notified that the court has certified the case to proceed as
a class action. Everest & Jennings has received and filed responses and
objections to a document request, but further action has been deferred to allow
the parties to discuss possible settlement. Everest & Jennings has ordered the
parties to file and plaintiff's counsel has filed monthly reports on the status
of settlement discussions since September 1996. There are numerous defenses
which Everest & Jennings intends to assert to the allegations in the first
amended complaint if settlement cannot be reached on acceptable terms. Under
Everest & Jennings' directors and officers insurance policy, Everest & Jennings
has coverage against liabilities incurred by its directors and officers, subject
to a self-insured retention of $150,000 (which has been exceeded by defense
costs incurred to date). The carrier has contended that fifty percent of the
liability and expenses in the case must be allocated to Everest & Jennings,
which is not an insured defendant, and fifty percent to the insured former
director and officer defendants. This proceeding constitutes an Everest &
Jennings Proceeding, which is covered under BIL's indemnification obligations
pursuant to the terms and provisions of the Stockholder Agreement.
Die Cast Products, Inc., a former subsidiary of Everest & Jennings, was
named as a defendant in a lawsuit filed by the State of California pursuant to
the Comprehensive Environmental Response, Compensation and Liability Act 42
U.S.C. Sections 9601 et seq. Everest &
-20-
<PAGE> 22
Jennings was originally notified of this action on December 10, 1992. A
settlement was reached at an October 5, 1995 Mandatory Settlement Conference
before Judge Rea in the Federal District Court of the Central District of
California. The state of California has agreed to accept the sum of $2.6 million
as settlement for all past costs and future remedial work. Everest & Jennings'
share of the settlement with the state of California has amounted to $41,292.30,
which sum was paid on January 3, 1997. No further claims or assessments with
respect to this matter are anticipated at this time. This proceeding constitutes
an Everest & Jennings Proceeding, which is covered under BIL's indemnification
obligations pursuant to the terms and provisions of the Stockholder Agreement.
In March, 1993, E&J received a notice from the U.S. Environmental
Protection Agency ("EPA") regarding an organizational meeting of generators with
respect to the Casmalia Resources Hazardous Waste Management Facility ("Casmalia
Site") in Santa Barbara County, CA. The EPA alleges that the Casmalia Site is an
inactive hazardous waste treatment, storage and disposal facility which accepted
large volumes of commercial and industrial wastes from 1973 until 1989. In late
1991, the Casmalia Site owner/operator abandoned efforts to actively pursue site
permitting and closure and is currently conducting only minimal maintenance
activities. An agreement in principle now has been reached between the Casmalia
Steering Committee ("CSC") and the EPA for a settlement of the majority of the
Casmalia site liability. The Steering Committee represents approximately 50 of
the largest volume generators at the Casmalia site. It is anticipated that the
agreement will be formalized and embodied in a Consent Decree in the summer and
fall of 1997. Pursuant to the settlement, the CSC members are committing to
perform and fund Phase I work at the site. It is estimated that the Phase I work
being committed to will cost approximately $30 to $35 million dollars and will
take three to five years to complete. This cost will be allocated to Steering
Committee members based upon their volume of waste sent to the site. Everest &
Jennings accounts for 0.8% of the waste. Thus, by participating in the Phase I
settlement, Everest & Jennings has committed to payments of approximately
$280,000 to be spread over a three to five year period. Pursuant to the
settlement, Everest & Jennings will be released from further obligation for
thirty (30) years. In addition, the Steering Committee companies are seeking to
recover from the owner and operator of the site. Any such recovery will diminish
E&J's' payout pursuant to the settlement. This proceeding constitutes an Everest
& Jennings Proceeding, which is covered under BIL's indemnification obligations
pursuant to the terms and provisions of the Stockholder Agreement.
In 1989, a patent infringement case was initiated against E&J and other
defendants in the U.S. District Court, Central District of California. E&J
prevailed at trial with a directed verdict of patent invalidity and
non-infringement. The plaintiff filed an appeal with the U.S. Court of Appeals
for the Federal Circuit. On March 31, 1993, the Court of Appeals vacated the
District Court's decision and remanded the case for trial. Impacting the retrial
of this litigation was a re-examination proceeding before the Board of Patent
Appeals with respect to the subject patent. A ruling was rendered November 23,
1993 sustaining the claim of the patent which E&J Inc. has been charged with
infringing. Upon the issuance of a patent re-examination certificate
-21-
<PAGE> 23
by the U.S. Patent Office, the plaintiff presented a motion to the District
Court requesting a retrial of the case. E&J presented a Motion for Summary
Judgment of Noninfringement based in part upon the November 23, 1993 decision of
the Board of Patent Appeals. The Motion was granted in follow-up conferences and
an official Judgment was entered November 17, 1994. Following the appeal by the
plaintiffs, the case has been remanded to the U.S. District Court, Central
District of California, for further consideration. E&J intends to contest this
case vigorously. The ultimate liability of E&J, if any, cannot be determined at
this time. This proceeding constitutes an Everest & Jennings Proceeding, which
is covered under BIL's indemnification obligations pursuant to the terms and
provisions of the Stockholder Agreement.
Following a jury trial on July 15, 1996, a verdict was rendered in the
District Court of the First Judicial District of the State of New Mexico in a
civil product liability law suit (Chris Trew et al. vs. Smith and Davis
Manufacturing Company, Inc., No. SF95-354) against Smith & Davis Manufacturing
Company, a wholly-owned subsidiary of Everest & Jennings ("Smith & Davis"), in
the amount of $635,698.12 actual damages, prejudgment interest and costs, plus
$4 million punitive damages. The suit was instituted on February 25, 1995 by the
children and surviving heirs and personal representatives of a nursing home
patient in Carlsbad, New Mexico who died on September 28, 1993 after her head
became pinned between a bed rail allegedly manufactured by Smith & Davis and her
bed. The suit alleged that the bed rail in question was defective and unsafe for
its intended purpose, that Smith & Davis was negligent in designing,
manufacturing, testing and marketing such bed rails, and that the negligence of
the nursing home in question was the proximate cause of decedent's injuries and
death. The nursing home reached a settlement with Plaintiffs prior to trial.
Judgment was entered on the jury verdict, which bears interest at the rate of
15% from August 30, 1996 until paid. On October 15, 1996, Plaintiffs filed a
related case in the Circuit Court of the County of St. Louis, Missouri (Chris
Trew, et al. v. Everest & Jennings, et al., Cause No. 96CC-000456, Division
39), which seeks a declaratory judgment against Everest & Jennings and BIL to
pierce their respective corporate veils and holding them jointly and severally
liable for the full amount of the New Mexico judgment. On February 26, 1997, the
parties agreed in principle to a proposed settlement in which the Plaintiffs
would receive $3 million, of which Everest & Jennings estimates that
approximately $1.5 million will be paid by Everest & Jennings' insurance
carriers, however, Everest & Jennings may seek additional recovery from the
insurance carriers. The amounts required to be paid in the proposed settlement
in excess of any insurance recoveries will be borne, in whole or in part, by BIL
under the indemnification terms and provisions contained in the Stockholder
Agreement and/or through the Company's right of offset under the Company's
subordinated promissory note to BIL dated as of December 10, 1996 (the "BIL
Note"), in the principal amount of $4 million.
While the results of the lawsuits and other proceedings referred to
above cannot be predicted with certainty, management does not expect that the
ultimate liabilities, if any, will have a material adverse effect on the
consolidated financial position, results of operations or cash flows of the
Company.
The Company and its subsidiaries are parties to other lawsuits and
other proceedings arising out of the conduct of its ordinary course of business,
including those relating to product liability and the sale and distribution of
its products. While the results of such lawsuits and other proceedings cannot be
predicted with certainty, management does not expect
-22-
<PAGE> 24
that the ultimate liabilities, if any, will have a material adverse effect on
the consolidated financial position, results of operations or cash flows of the
Company.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS:
A special meeting (the "Special Meeting") of the Company's stockholders
was held on November 27, 1996 to approve the following matters:
1. The issuance of shares of capital stock of the Company pursuant to
an Amended and Restated Agreement and Plan of Merger dated as of September 3,
1996 and amended as of October 1, 1996, by and among the Company, E&J
Acquisition Corp. ("Acquisition Corp."), a wholly-owned subsidiary of the
Company, Everest & Jennings, and BIL, providing for the merger of Acquisition
Corp. with and into Everest & Jennings.
2. To adopt an amendment to Article FOURTH of the Certificate of
Incorporation of the Company (the "Certificate of Incorporation") to increase
the number of authorized shares of the common stock of the Company from
40,000,000 shares to 60,000,000 shares.
3. To adopt an amendment to Article NINTH of the Certificate of
Incorporation to require that stockholder action be taken at an annual meeting
of stockholders or at a special meeting of stockholders and prohibit stockholder
action by written consent.
4. To adopt an amendment to Article ELEVENTH of the Certificate of
Incorporation to, among other things, provide that directors be removed only for
cause and only with the approval of the holders of at least 50% of the voting
power of the Company entitled to vote generally in the election of directors.
5. To adopt an amendment to Article TWELFTH of the Certificate of
Incorporation to provide that the stockholder vote required to alter, amend, or
repeal certain provisions of the Company Bylaws, or to adopt any provision
inconsistent therewith, shall be 80% of the voting power of the Company entitled
to vote generally in the election of directors.
6. To approve an amendment to the Company's Incentive Program to
increase the maximum number of shares of the common stock of the Company
available under the Incentive Program by 900,000 shares.
-23-
<PAGE> 25
As of the record date of October 11, 1996, 14,209,895 shares of the common stock
of the Company were issued and outstanding. Tabulations for the proposals voted
at the Special Meeting are set forth below:
<TABLE>
<CAPTION>
For Against/Withheld Abstain
--- ---------------- -------
<S> <C> <C> <C>
Proposal No. 1 8,974,876 130,669 107,024
Proposal No. 2 9,225,439 307,202 38,124
Proposal No. 3 7,848,233 1,192,439 171,906
Proposal No. 4 7,164,461 1,866,451 181,657
Proposal No. 5 7,108,604 1,930,334 173,631
Proposal No. 6 8,155,494 962,591 93,584
</TABLE>
All of such proposals were approved at the Special Meeting.
-24-
<PAGE> 26
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON STOCK AND RELATED STOCKHOLDER MATTERS:
(a) The Common Stock of the Company is traded on the New York
Stock Exchange (Symbol: GFI). The following provides the high and low sales
prices for the period from January 1, 1995 through March 20, 1997 as reported on
the New York Stock Exchange.
<TABLE>
<CAPTION>
High Sales Price Low Sales Price
---------------- ---------------
<S> <C> <C>
1995
First Quarter 4 1/2 3 1/4
Second Quarter 4 1/4 3
Third Quarter 4 5/8 3
Fourth Quarter 4 5/8 3 1/4
1996
First Quarter 5 3 1/8
Second Quarter 9 7/8 4 1/4
Third Quarter 9 1/8 6 1/2
Fourth Quarter 9 1/2 6 5/8
1997
First Quarter, through
March 20, 1997 13 3/4 8 1/2
</TABLE>
(b) As of the close of business on March 20, 1997, the number
of holders of record of Common Stock of the Company was 595.
(c) On December 10, 1996, the Company entered into a
syndicated three-year senior secured revolving credit facility (the "Credit
Facility") for up to $55 million of borrowings, including letters of credit and
banker's acceptances, arranged by IBJ Schroder Bank & Trust Company ("IBJ
Schroder"), as agent. The proceeds from the Credit Facility were used to (i)
refinance certain existing indebtedness of the Company, including the
indebtedness (a) under the terms of the Note and Warrant Agreement dated as of
March 12, 1992, as amended (the "John Hancock Note and Warrant Agreement"), with
John Hancock Mutual Life Insurance Company ("John Hancock"), and (b) to Chase
Manhattan Bank, and (ii) provide for the nationwide roll-out of the Graham-Field
Express program and for the ongoing working capital needs of the Company. The
credit facility is secured by the Company's receivables, inventory and proceeds
thereof.
-25-
<PAGE> 27
Under the terms of the Credit Facility, the Company is
prohibited from declaring, paying or making any dividend or distribution on any
shares of the common stock or preferred stock of the Company (other than
dividends or distributions payable in its stock, or split-ups or
reclassifications of its stock) or apply any of its funds, property or assets to
the purchase, redemption or other retirement of any common or preferred stock,
or of any options to purchase or acquire any such shares of common or preferred
stock of the Company. Notwithstanding the foregoing restrictions, the Company is
permitted to pay cash dividends in any fiscal year in an amount not to exceed
the greater of (i) the amount of dividends due BIL under the terms of the Series
B and Series C Preferred Stock in any fiscal year, or (ii) 12.5% of net income
of the Company on a consolidated basis, provided, that no event of default shall
have occurred and be continuing or would exist after giving effect to the
payment of the dividends.
The Company anticipates that for the foreseeable future any
earnings will be retained for use in its business and accordingly, does not
anticipate the payment of cash dividends, other than to BIL in accordance with
the terms and provisions of the Series B and Series C Preferred Stock.
-26-
<PAGE> 28
ITEM 6. SELECTED FINANCIAL DATA:
Selected Financial Data
- -----------------------
<TABLE>
<CAPTION>
Year Ended December 31,
-----------------------
1996 1995 1994 1993 1992
--------------- -------------- ------------- ------------- --------------
<S> <C> <C> <C> <C> <C>
Statement of Operations
Data:
Net Revenues $ 143,642,000 $ 112,414,000 $ 106,026,000 $ 101,607,000 $ 92,397,000
=============== ============= ============= ============= ============
(Loss) Income
before extraordinary item
and cumulative effect
of change in accounting
principle $ (11,873,000) $ 1,047,000 $ (1,979,000) $ (3,037,000) $ 1,805,000
Extraordinary item (736,000) - - - -
Cumulative effect of change
in accounting principle - - - 530,000 -
-------------- ------------- ------------ ------------ -----------
Net (loss) income $ (12,609,000) $ 1,047,000 $ (1,979,000) $ (2,507,000) $ 1,805,000
============== ============= ============ ============ ============
Net (loss) income per common share:
Before extraordinary item
and cumulative effect of
change in accounting
principle $ (.76) $ .07 $ (.14) $ ( .22) $ .13
Extraordinary item (.05) - - - -
Cumulative effect of change
in accounting principle - - - .04 -
--------------- ------------- ------------ ------------- ------------
Net (loss) income per
common share $ (.81) $ .07 $ (.14) $ (.18) $ .13
============== ============= ============ ============ ============
Weighted average number of
common and equivalent
shares outstanding 15,557,000 14,315,000 13,862,000 13,779,000 13,702,000
============== =============== ============== =============== ===============
</TABLE>
-27-
<PAGE> 29
Selected Financial Data
- -----------------------
<TABLE>
<CAPTION>
Year Ended December 31,
-----------------------
Balance Sheet Data: 1996 1995 1994 1993 1992
------------ ------------ ------------ ----------- ------------
<S> <C> <C> <C> <C> <C>
Current Assets $ 98,468,000 $ 56,640,000 $ 53,584,000 $49,272,000 $ 52,445,000
------------ ------------ ------------ ----------- ------------
Current Liabilities $ 84,404,000 $ 21,579,000 $ 24,195,000 $19,275,000 $ 18,457,000
------------ ------------ ------------ ----------- ------------
Total Assets $207,194,000 $103,011,000 $102,454,000 $99,891,000 $100,043,000
------------ ------------ ------------ ----------- ------------
Long-term debt (including
capital leases due after one
year) $ 6,535,000 $ 1,462,000 $ 2,107,000 $ 2,719,000 $ 1,950,000
------------ ------------ ------------ ----------- -----------
Guaranteed Senior Notes (net
of current maturities) $ - $ 19,000,000 $20,000,000 $20,000,000 $20,000,000
------------ ------------ ----------- ----------- -----------
Stockholders' equity $114,503,000 $ 60,970,000 $56,152,000 $57,897,000 $59,636,000
------------ ------------ ----------- ----------- -----------
</TABLE>
-28-
<PAGE> 30
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS:
FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include plans and objectives of management for future operations,
including plans and objectives relating to the future economic performance and
financial results of the Company. The forward-looking statements relate to (i)
the expansion of the Company's market share, (ii) the Company's growth into new
markets, (iii) the development of new products and product lines to appeal to
the needs of the Company's customers, (iv) the opening of new distribution and
warehouse facilities, including the expansion of the Graham-Field Express
program, (v) obtaining regulatory and governmental approvals, (vi) the upgrading
of the Company's technological resources and systems and (vii) the retention of
the Company's earnings for use in the operation and expansion of the Company's
business.
Important factors and risks that could cause actual results to differ
materially from those referred to in the forward-looking statements include, but
are not limited to, the effect of economic and market conditions, the impact of
the consolidation of healthcare practitioners, the impact of healthcare reform,
opportunities for acquisitions and the Company's ability to effectively
integrate acquired companies, the Company's ability to obtain an alternative
source of supply for homecare beds, the termination of the Company's Exclusive
Wheelchair Supply Agreement with P.T. Dharma, the ability of the Company to
maintain its gross profit margins, the ability to obtain additional financing to
expand the Company's business, the failure of the Company to successfully
compete with the Company's competitors that have greater financial resources,
the loss of key management personnel or the inability of the Company to attract
and retain qualified personnel, adverse litigation results, the acceptance and
quality of new software and hardware products which will enable the Company to
expand its business, the acceptance and ability to manage the Company's
operations in foreign markets, possible disruptions in the Company's computer
systems or distribution technology systems, possible increases in shipping rates
or interruptions in shipping service, the level and volatility of interest rates
and currency values, the impact of current or pending legislation and
regulation, as well as the risks described from time to time in the Company's
filings with the Securities and Exchange Commission, which include this Annual
Report on Form 10-K, and the section entitled "Risk Factors" in the Company's
Registration Statement on Form S-4 dated as of October 18, 1996.
The forward-looking statements are based on current expectations and
involve a number of known and unknown risks and uncertainties that could cause
the actual results, performance and/or achievements of the Company to differ
materially from any future results, performance or achievements, express or
implied, by the forward-looking statements. Readers are cautioned not to place
undue reliance on these forward-looking statements, and that in light
-29-
<PAGE> 31
of the significant uncertainties inherent in forward-looking statements, the
inclusion of such statements should not be regarded as a representation by the
Company or any other person that the objectives or plans of the Company will be
achieved.
RESULTS OF OPERATIONS
On August 28, 1997, the Company acquired all of the issued and
outstanding shares of the capital stock of Medapex, which was accounted for as a
"pooling of interests." Accordingly, the Company's financial statements for
periods prior to the combination have been restated to include the results of
Medapex for all periods.
Operating Revenues
1996 compared to 1995. Operating revenues were $143,083,000 for the
year ended December 31, 1996, or 28% higher than the year ended December 31,
1995. The increase in operating revenues was primarily attributable to the
Company's expansion of its C.A.P. program, the introduction of the Graham-Field
Express program, the addition of new product lines and the acquisition of
Everest & Jennings on November 27, 1996.
In March 1996, Graham-Field Express was introduced to offer "same-day"
and "next-day" service to home healthcare dealers of certain strategic home
healthcare products, including Temco patient aids, adult incontinence products,
Everest & Jennings wheelchairs, Smith & Davis homecare beds, nutritional
supplements and other freight and time sensitive products. Revenues attributable
to Graham-Field Express were approximately $14,431,000 for the year ended
December 31, 1996. The Company plans to open an additional three (3) to four (4)
Graham-Field Express sites in 1997 and eight (8) in 1998. A new Graham-Field
Express location is scheduled to open in Baltimore, Maryland in April 1997. By
late 1999, the Company plans to have a total of approximately twenty-five (25)
Graham-Field Express locations serving all of the major U.S. markets.
On September 4, 1996, the Company acquired V.C. Medical, a regional
home healthcare wholesaler located in Puerto Rico. V.C. Medical currently
operates as Graham-Field Express (Puerto Rico). Revenues attributable to
Graham-Field Express (Puerto Rico) were approximately $1,766,000 for the year
ended December 31, 1996.
On November 27, 1996, the Company completed its acquisition of Everest
& Jennings. The Company believes that the combination of Everest & Jennings'
manufacturing operations with the Company's cost-effective delivery systems and
advanced technology systems will increase the Company's presence in the home
healthcare market with a greater level of service and efficiency, and a broader
portfolio of products. The coordination of the manufacturing and distribution of
the wheelchair and homecare bed product lines, which represent the leading
product lines in the home healthcare market, will enhance the Company's position
as a leading "one-stop-shop" distributor of medical products. The Everest &
Jennings name, a symbol of quality for more than fifty years, has enabled the
Company to introduce its Temco home healthcare product line and other
proprietary product lines into the rehabilitation marketplace, a virtually
untapped marketplace for the Company in the past. Revenues attributable
-30-
<PAGE> 32
to Everest & Jennings for the period from the date of acquisition to December
31, 1996 were approximately $3,634,000.
The increase in operating revenues was achieved despite the decline in
sales of approximately $5,905,000 to Apria Healthcare Group, Inc. ("Apria") for
the year ended December 31, 1996 as compared to the prior year. The Company's
supply agreement with Apria expired on December 31, 1995.
1995 compared to 1994. Operating revenues were $112,113,000 for the
year ended December 31, 1995, or 6% higher than the year ended December 31,
1994. The increase in operating revenues was primarily attributable to improved
service levels, improvements in the Company's distribution network, the
development of new sales and marketing programs and the expansion of the
Company's product lines. During 1995, the Company introduced over 100 new
products including the Temco deluxe four-wheel walkabout, the John Bunn Nebulite
II medication compressor and the Labtron automatic wrist blood pressure monitor.
In addition, 1995 revenues also included approximately $935,000, net of
elimination of intercompany sales, attributable to the acquisition of National
Medical Excess Corp., effective as of July 1, 1995.
The revenue increase was achieved despite the decline in sales to Apria
of 21% for the year ended December 31, 1995 as compared to the prior year. The
Company's supply agreement with Apria terminated on December 31, 1995. During
1995 and 1994, the Company's product sales to Apria were approximately $8.1
million and $10.3 million, respectively, which represented approximately 8% and
11%, respectively, of the Company's product sales. The Company's sales to Apria
generated gross profit margins of approximately 20%, which is significantly
lower than the Company's sales to its other customers which generate gross
profit margins of approximately 33%.
Interest and Other Income
1996 compared to 1995. Interest and other income increased from
$301,000 in 1995 to $559,000 in 1996. The increase is primarily due to the gain
recognized by the Company and royalties received by the Company in connection
with the sale of the Gentle Expressions(R) breast pump product line, and
interest income on certain notes receivable.
1995 compared to 1994. Interest and other income increased from $75,000
in 1994 to $301,000 in 1995. The increase is primarily due to the receipt of
approximately $200,000 relating to an insurance recovery and a favorable
settlement of a contractual dispute.
Cost of Revenues
1996 compared to 1995. Cost of revenues as a percentage of operating
revenue for 1996 remained relatively unchanged from the prior year, at 70%. Due
to manufacturing
-31-
<PAGE> 33
efficiencies and improved purchasing activities, Graham-Field maintained its
gross profit margin despite increased competition.
1995 compared to 1994. Cost of revenues as a percentage of operating
revenue remained relatively unchanged from the prior year, at 70%. Due to
manufacturing efficiencies and improved purchasing activities, the Company
maintained its gross profit margin despite increased competition.
Selling, General and Administrative Expenses
1996 compared to 1995. Selling, general and administrative expenses as
a percentage of operating revenues decreased to 24% in 1996 from 26% in 1995.
The decrease is attributable to a number of factors, including the expansion of
the Graham-Field Express program in 1996, which contributes revenue with a lower
percentage of selling, general and administrative expenses, as well as continued
efficiencies generated by the Company's distribution network.
The Company is currently in the process of evaluating its computer
software and databases to ensure that any modifications required to be year 2000
compliant are made in a timely manner. Management does not expect the financial
impact of such modifications to be material to the Company's financial position
or results of operations in any given year.
1995 compared to 1994. Selling, general and administrative expenses
decreased $2,518,000 or 8% in 1995. As a percentage of operating revenues,
selling, general and administrative expenses decreased to 26% from 30%. The
decrease was primarily due to cost reduction programs, the continued
efficiencies generated by the Company's distribution network and investments in
new business systems, and the non-recurring cost of approximately $1,321,000
recorded in the fourth quarter of 1994.
Interest Expense
1996 compared to 1995. Interest expense for 1996 decreased by $142,000
or 5% as compared to 1995. The decrease is primarily due to lower interest rates
on reduced average borrowings.
1995 compared to 1994. Interest expense increased $23,000 or 1%,
principally due to an increase in interest rates from the prior year. Interest
expense for the last six months of 1995 decreased compared to the same period in
the prior year due to a decrease in borrowings during the period. The Company
reduced its borrowings as a result of increased earnings, and the net proceeds
of $3,471,000 realized from an offshore private placement of 1,071,655 shares of
common stock completed in September 1995.
-32-
<PAGE> 34
Merger and Other Related Charges
1996 compared to 1995. During the fourth quarter of 1996, the Company
recorded charges of $15.8 million related to the acquisition of Everest &
Jennings. The charges included $12.8 million associated with the write-off of
purchased in-process research and development costs and $3.0 million of merger
expenses related to severance payments, the write-off of certain unamortized
catalog and software costs with no future value, the accrual of costs to vacate
certain of the Company's facilities, and the cost of certain insurance policies.
Net (Loss) Income
1996 compared to 1995. Loss before income taxes and extraordinary item
was $8,955,000, as compared to income before income taxes of $1,741,000 for the
prior year. The loss before income taxes and extraordinary item for 1996
includes certain charges of $15.8 million relating to the acquisition of Everest
& Jennings. The charges include $12,800,000 associated with the write-off of
purchased in-process research and development costs and $3,000,000 related to
merger expenses.
Net loss after the charge for the extraordinary item related to the
early retirement of the indebtedness underlying the John Hancock Note and
Warrant Agreement (the "John Hancock Indebtedness") was $12,609,000 in 1996, as
compared to net income of $1,047,000 for 1995. The extraordinary item of
$736,000 (net of tax benefit of $383,000) relates to the "make-whole" payment
and write-off of unamortized deferred financing costs associated with the early
retirement of the John Hancock Indebtedness.
The Company recorded income tax expense of $2,918,000 for the year
ended December 31, 1996, as compared to $694,000 for the prior year. As of
December 31, 1996, the Company had a deferred tax asset of $938,000, primarily
comprised of net operating loss carryforwards (including those acquired in
connection with an acquisition) and investment, research and development, jobs
tax and alternative minimum tax credits. The Company has provided a valuation
allowance of approximately $400,000 in the fourth quarter of 1996 because
certain tax credits are available only through their expiration dates, and only
after the utilization of available net operating loss carryforwards. A full
valuation allowance has been recognized to offset the deferred assets related to
the acquired tax attributes. If realized, the tax benefit for those items will
be recorded as a reduction of goodwill. In addition, the Company has provided an
additional valuation allowance of $600,000 in the fourth quarter of 1996 as a
charge to income tax expense against a portion of the remaining net deferred tax
asset at December 31, 1996 due to the recent acquisition of Everest & Jennings.
The balance of the deferred tax asset will continue to be evaluated by
management as to its realizability on a quarterly basis. The amount of the
deferred tax asset considered realizable could be reduced in the near future if
estimates of future taxable income during the carryforward period are reduced.
Uncertainties which may
-33-
<PAGE> 35
impact the future realizability but are not expected to occur, include a decline
in sales and margins resulting from a possible loss of market share and
increased competition.
1995 compared to 1994. Income before income taxes was $1,741,000 as
compared to a loss before income taxes of $2,714,000 for the prior year. The
increase in income before income taxes is primarily due to the increase in
revenues and the decrease in selling, general and administrative expenses.
Net income was $1,047,000 as compared to a net loss of $1,979,000 for
the prior year. The Company recorded income tax expense of $694,000 for the year
ended December 31, 1995, as compared to an income tax benefit of $735,000 for
the prior year. As of December 31, 1995, the Company had recorded a deferred tax
asset of $3,084,000, primarily comprised of net operating loss carryforwards and
investment, research and development, jobs tax and alternative minimum tax
credits. At December 31, 1995, based upon the Company's expectation that future
taxable income will be sufficient to utilize the carryforwards prior to December
31, 2009, the Company did not record a valuation allowance on the deferred tax
assets, except for an allowance of $55,000 related to tax assets recorded for
acquired carryforwards.
The Company's business has not been materially affected by inflation.
Liquidity and Capital Resources
The Company had working capital of $14,064,000, $35,061,000 and
$29,389,000 at December 31, 1996, 1995 and 1994, respectively. The decrease in
working capital for the period ended December 31, 1996 is primarily attributable
to the early retirement of the John Hancock Indebtedness and certain accrued
expenses related to the Everest & Jennings acquisition. The Company retired the
John Hancock Indebtedness with a portion of the proceeds from the Company's
Credit Facility with IBJ Schroder, which borrowings are classified as current
liabilities.
The increase in working capital for the period ended December 31, 1995
is primarily attributable to the cash provided by the Company's net income of
$1,047,000, which reflects $3,347,000 of depreciation and amortization expense.
In addition, the Company raised $3,471,000 of additional capital, net of
expenses, through an offshore private placement of 1,071,655 shares of its
common stock completed in September 1995.
Cash provided by operations for the year ended December 31, 1996 was
$3,770,000. The principal reason for the cash provided by operations was the
Company's operating income after adjustments for non-cash charges, partially
offset by the aggregate increase in accounts receivable and inventory in excess
of related payables.
-34-
<PAGE> 36
Financing
On December 10, 1996, the Company entered into a Credit Facility for up
to $55 million of borrowings, including letters of credit and banker's
acceptances, arranged by IBJ Schroder, as agent. The proceeds from the Credit
Facility were used to (i) refinance certain existing indebtedness of the
Company, including the indebtedness (a) under the John Hancock Note and Warrant
Agreement and (b) to The Chase Manhattan Bank and (ii) to provide for working
capital needs of the Company. Under the terms of the Credit Facility, borrowings
bear interest, at the option of the Company at the bank's prime rate (8.25% at
December 31, 1996) or 2.25% above LIBOR, or 1.5% above the bank's bankers'
acceptance rate. The Credit Facility is secured by the Company's receivables,
inventory and proceeds thereof.
The Credit Facility contains certain customary terms and provisions,
including limitations with respect to the incurrence of additional debt, liens,
transactions with affiliates, consolidations, mergers and acquisitions, sales of
assets, dividends and other distributions (other than the payment of dividends
to BIL in accordance with the terms of the Company's Series B and Series C
Cumulative Convertible Preferred Stock). In addition, the Credit Facility
contains certain financial covenants, which become effective as of the end of
the fiscal quarter ending June 30, 1997, including a cash flow coverage and
leverage ratio, and an earnings before interest and taxes covenant.
Under the terms of the Credit Facility, the Company is prohibited from
declaring, paying or making any dividend or distribution on any shares of the
common stock or preferred stock of the Company (other than dividends or
distributions payable in its stock, or split-ups or reclassifications of its
stock) or apply any of its funds, property or assets to the purchase, redemption
or other retirement of any common or preferred stock, or of any options to
purchase or acquire any such shares of common or preferred stock of the Company.
Notwithstanding the foregoing restrictions, the Company is permitted to pay cash
dividends in any fiscal year in an amount not to exceed the greater of (i) the
amount of dividends due BIL under the terms of the Series B and Series C
Preferred Stock in any fiscal year, or (ii) 12.5% of the net income of the
Company on a consolidated basis, provided that no event of default shall have
occurred and be continuing or would exist after giving effect to the payment of
the dividends.
On July 18, 1996, an affiliate of BIL provided the Company with a loan
in the amount of $4,000,000, at an effective interest rate of 8.8%. The loan was
used to fund the acquisition of V.C. Medical and for general corporate purposes.
On December 10, 1996, the loan was converted into the BIL Note, which matures on
April 1, 2001, with interest payable quarterly at an effective rate of 7.7% per
year. Under the terms of the BIL Note, the Company has the right to reduce the
principal amount of the BIL Note in the event punitive damages are awarded
against the Company or any of its subsidiaries which relate to any existing
product liability claims of Everest & Jennings and/or its subsidiaries involving
a death prior to September 3, 1996.
-35-
<PAGE> 37
On November 27, 1996, the Company acquired Everest & Jennings in a
merger transaction. In the merger, each share of the common stock of Everest &
Jennings, other than shares of the common stock of Everest & Jennings cancelled
pursuant to the merger, was converted into the right to receive .35 shares of
the common stock of the Company. In connection with the merger, 2,522,691 shares
of common stock of the Company were issued in exchange for the common stock of
Everest & Jennings. The Company's common stock was valued at $7.64 per share,
which represented the average closing market price of the Company's common stock
for the period three business days immediately prior to and three business days
immediately after the announcement of the execution of the merger agreement. In
addition, in connection with, and at the effective time of the merger:
(i) BIL was issued 1,922,242 shares of common stock of the
Company in consideration of the repayment of the HSBC
Indebtedness, which was guaranteed by BIL. The proceeds of
such stock purchase were contributed by the Company to Everest
& Jennings immediately following the merger and used to
discharge the HSBC Indebtedness.
(ii) The Company issued $61 million stated value of the Series B
Preferred Stock to BIL in exchange for certain indebtedness of
Everest & Jennings owing to BIL and shares of E&J preferred
stock owned by BIL. The Series B Preferred Stock is entitled
to a dividend of 1.5% per annum payable quarterly, votes on an
as-converted basis as a single class with the common stock of
the Company and the Series C Preferred Stock (as defined
below), is not subject to redemption and is convertible into
shares of the common stock of the Company (x) at the option of
the holder thereof, at a conversion price of $20 per share
(or, in the case of certain dividend payment defaults, at a
conversion price of $15.50 per share), (y) at the option of
the Company, at a conversion price equal to current trading
prices (subject to a minimum conversion price of $15.50 and a
maximum conversion price of $20 per share) and (z)
automatically on the fifth anniversary of the date of issuance
at a conversion price of $15.50 per share. Such conversion
prices are subject to customary antidilution adjustments.
Based on an independent valuation, the fair value ascribed to
the Series B Preferred Stock was $28,200,000.
(iii) BIL was issued $10 million stated value of the Series C
Preferred Stock, the proceeds of which are available to the
Company for general corporate purposes. The Series C Preferred
Stock is entitled to a dividend of 1.5% per annum payable
quarterly, votes on an as-converted basis as a single class
with the common stock of Company and the Series B Preferred
-36-
<PAGE> 38
Stock, is subject to redemption as a whole at the option of
the Company on the fifth anniversary of the date of issuance
at stated value and, if not so redeemed, will be convertible
into shares of the common stock of the Company automatically
on the fifth anniversary of the date of issuance at a
conversion price of $20 per share, subject to customary
antidilution adjustments. Based on an independent valuation,
the fair value ascribed to the Series C Preferred Stock was
$3,400,000.
(iv) Certain indebtedness in the amount of $4 million owing by the
Company to BIL was exchanged for an equal amount of unsecured
subordinated indebtedness of the Company maturing on April 1,
2001 and bearing interest at the effective rate of 7.7% per
annum, which was evidenced by the BIL Note.
On March 4, 1996, the Company sold its Gentle Expressions breast pump
product line to The Lumiscope Company, Inc. for a purchase price of $1,000,000,
of which $500,000 was paid in cash with the balance in a secured subordinated
promissory note in the aggregate principal amount of $500,000, payable over 48
months plus interest at the prime rate of interest plus 1%.
On September 4, 1996, the Company acquired substantially all of the
assets of V.C. Medical for a purchase price consisting of $1,703,829 in cash and
the issuance of 32,787 shares of common stock valued at $7.625 per share.
On February 28, 1997, Everest & Jennings Canada acquired substantially
all of the assets of Motion 2000 and Motion 2000 Quebec, in consideration of the
issuance of 187,733 shares of common stock valued at $11.437 per share.
On March 7, 1997, E&J acquired all of the capital stock of Kuschall, in
consideration of the issuance of 116,154 shares of common stock valued at $13.00
per share.
The Company anticipates that the cash flow from operations, together
with the current cash balance, and the proceeds from the Credit Facility will be
sufficient to meet its working capital requirements.
-37-
<PAGE> 39
ANNUAL REPORT ON FORM 10-K/A-2
ITEM 8, ITEM 14(a)(1) and (2),(c) and (d)
LIST OF FINANCIAL STATEMENTS
AND
FINANCIAL STATEMENT SCHEDULE
FINANCIAL STATEMENTS
CERTAIN EXHIBITS
FINANCIAL STATEMENT SCHEDULE
YEAR ENDED DECEMBER 31, 1996
GRAHAM-FIELD HEALTH PRODUCTS, INC.
HAUPPAUGE, NEW YORK
<PAGE> 40
FORM 10-K/A-2--ITEM 8, ITEM 14(a)(1) and (2) and (d)
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
LIST OF FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULE
The following consolidated financial statements of Graham-Field Health Products,
Inc. and subsidiaries are included in Item 8:
Report of Independent Auditors...............................................F-2
Consolidated balance sheets--
December 31, 1996 and 1995..................................................F-3
Consolidated statements of operations--
Years ended December 31, 1996, 1995 and 1994................................F-5
Consolidated statements of stockholders' equity--
Years ended December 31, 1996, 1995 and 1994................................F-6
Consolidated statements of cash flows--
Years ended December 31, 1996, 1995 and 1994................................F-7
Notes to consolidated financial statements--
December 31, 1996...........................................................F-9
The following consolidated financial statement schedule of Graham-Field
Health Products, Inc. and subsidiaries is included in Item 14(d):
Schedule II--Valuation and qualifying accounts..............................F-37
All other schedules for which provision is made in the applicable accounting
regulation of the Securities and Exchange Commission are not required under the
related instructions or are inapplicable, and therefore have been omitted.
F-1
<PAGE> 41
REPORT OF INDEPENDENT AUDITORS
Stockholders and Board of Directors
Graham-Field Health Products, Inc.
We have audited the accompanying consolidated balance sheets of Graham-Field
Health Products, Inc. and subsidiaries (the "Company") as of December 31, 1996
and 1995, and the related consolidated statements of operations, stockholders'
equity and cash flows for each of the three years in the period ended December
31, 1996. Our audits also included the financial statement schedule listed in
the Index at Item 14(a). These financial statements and schedule are the
responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements and schedule based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the consolidated financial position of
Graham-Field Health Products, Inc. and subsidiaries at December 31, 1996 and
1995, and the consolidated results of their operations and their cash flows for
each of the three years in the period ended December 31, 1996, in conformity
with generally accepted accounting principles. Also, in our opinion, the related
financial statement schedule, when considered in relation to the basic financial
statements taken as a whole, presents fairly in all material respects the
information set forth therein.
/s/ ERNST & YOUNG LLP
Melville, New York
March 10, 1997, except for
Note 2 paragraph 5, as to
which the date is
August 28, 1997
F-2
<PAGE> 42
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
December 31,
1996 1995
------------ ------------
ASSETS
Current assets:
<S> <C> <C>
Cash and cash equivalents $ 1,241,000 $ 226,000
Accounts receivable, less allowance for
doubtful accounts of $7,243,000 and
$1,811,000, respectively 45,703,000 23,112,000
Inventories 48,245,000 31,239,000
Other current assets 3,023,000 1,809,000
Recoverable and prepaid income taxes 256,000 254,000
------------ ------------
TOTAL CURRENT ASSETS 98,468,000 56,640,000
Property, plant and equipment, net 11,264,000 8,599,000
Excess of cost over net assets acquired, net of
accumulated amortization of $8,185,000 and
$7,212,000, respectively 91,412,000 29,291,000
Investment in leveraged lease -- 487,000
Deferred tax assets 938,000 3,084,000
Other assets 5,112,000 4,910,000
------------ ------------
TOTAL ASSETS $207,194,000 $103,011,000
============ ============
</TABLE>
See notes to consolidated financial statements.
F-3
<PAGE> 43
GRAHAM-FIELD HEALTH PRODUCTS, INC AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS -- (CONTINUED)
<TABLE>
<CAPTION>
December 31
1996 1995
------------- -------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
<S> <C> <C>
Note payable to bank $ 13,985,000 $ 2,100,000
Current maturities of long-term debt
and Guaranteed Senior Notes 2,016,000 1,621,000
Accounts payable 22,995,000 9,828,000
Acceptances payable 19,800,000 5,000,000
Accrued expenses 25,608,000 3,030,000
------------- -------------
TOTAL CURRENT LIABILITIES 84,404,000 21,579,000
Long-term debt 6,535,000 1,462,000
Other long-term liabilities 1,752,000 --
Guaranteed Senior Notes -- 19,000,000
------------- -------------
TOTAL LIABILITIES 92,691,000 42,041,000
STOCKHOLDERS' EQUITY
Series A preferred stock, par value $.01 per share:
authorized shares 300,000, none issued
Series B preferred stock, par value $.01 per share:
authorized shares 6,100, issued and outstanding 6,100 28,200,000 --
Series C preferred stock, par value $.01 per share:
authorized shares 1,000, issued and outstanding 1,000 3,400,000 --
Common stock, par value $.025 per share:
authorized shares 60,000,000, issued and outstanding
19,650,744 and 15,065,286, respectively 492,000 377,000
Additional paid-in capital 101,573,000 66,891,000
(Deficit) (18,995,000) (6,298,000)
Cumulative translation adjustment (12,000) --
------------- -------------
Subtotal 114,658,000 60,970,000
Notes receivable from sale of shares (155,000) --
------------- -------------
TOTAL STOCKHOLDERS' EQUITY 114,503,000 60,970,000
Commitments and contingencies ------------- -------------
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY $ 207,194,000 $ 103,011,000
============= =============
</TABLE>
See notes to consolidated financial statements.
F-4
<PAGE> 44
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
Year Ended December 31
1996 1995 1994
------------- ------------- -------------
Net revenues:
<S> <C> <C> <C>
Medical equipment and supplies $ 143,083,000 $ 112,113,000 $ 105,951,000
Interest and other income 559,000 301,000 75,000
------------- ------------- -------------
143,642,000 112,414,000 106,026,000
Costs and expenses:
Cost of revenues 99,641,000 78,525,000 74,079,000
Selling, general and administrative 34,578,000 29,428,000 31,964,000
Interest expense 2,578,000 2,720,000 2,697,000
Purchased in-process research &
development costs 12,800,000 -- --
Merger related charges 3,000,000 -- --
------------- ------------- -------------
152,597,000 110,673,000 108,740,000
------------- ------------- -------------
(Loss) income before income taxes (benefit)
and extraordinary item (8,955,000) 1,741,000 (2,714,000)
Income taxes (benefit) 2,918,000 694,000 (735,000)
------------- ------------- -------------
(Loss) income before extraordinary item (11,873,000) 1,047,000 (1,979,000)
Extraordinary loss on early retirement of
debt (net of tax benefit of $383,000) (736,000) -- --
------------- ------------- -------------
NET (LOSS) INCOME $ (12,609,000) $ 1,047,000 $ (1,979,000)
============= ============= =============
Net (loss) income per common share:
(Loss) income before extraordinary item $ (.76) $ .07 $ (.14)
Extraordinary loss on early retirement of debt (.05) -- --
------------- ------------- -------------
Net (loss) income per common share $ (.81) $ .07 $ (.14)
============= ============= =============
Weighted average number of common and
common equivalent shares 15,557,000 14,315,000 13,862,000
============= ============= =============
</TABLE>
See notes to consolidated financial statements.
F-5
<PAGE> 45
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
Series B Series C
Preferred Preferred Common Stock
Total Stock Stock Shares Amount
------------- ------------ ---------- ------------- -------------
<S> <C> <C> <C> <C> <C>
BALANCE, DECEMBER 31, 1993 $ 57,897,000 13,801,342 $ 345,000
Issuance of common stock on
exercise of stock options 192,000 149,250 4,000
Tax benefit from exercise of
stock options 42,000 -- --
Retirement of Treasury Stock --
Net loss (1,979,000) (28,943) (1,000)
------------- ------------ ---------- ------------- -------------
BALANCE, DECEMBER 31, 1994 56,152,000 13,921,649 348,000
Issuance of common stock
on exercise of stock options 172,000 86,500 2,000
Regulation S offering, net 3,471,000 1,071,655 27,000
Tax benefit from exercise of
stock options 38,000 -- --
Retirement of Treasury Stock -- (14,518)
Warrants issued in connection with debt 90,000 -- --
Net income 1,047,000 -- --
------------- ------------ ---------- ------------- -------------
BALANCE, DECEMBER 31, 1995 60,970,000 15,065,286 377,000
Issuance of common stock
on exercise of stock options 550,000 153,255 4,000
Issuance of stock in connection
with acquisitions 65,809,000 $ 28,200,000 $3,400,000 4,477,720 112,000
Tax benefit from exercise of
stock options 38,000 -- -- -- --
Retirement of Treasury Stock -- -- -- (45,517) (1,000)
Dividend accrued on Preferred Stock (88,000) -- --
Translation adjustment (12,000) -- -- -- --
Notes receivable from officers
for sale of shares (155,000) -- -- -- --
Net loss (12,609,000) -- --
------------- ------------ ---------- ------------- -------------
BALANCE, DECEMBER 31, 1996 $ 114,503,000 $ 28,200,000 $3,400,000 19,650,744 $ 492,000
============= ============ ========== ============= =============
</TABLE>
<TABLE>
<CAPTION>
Notes
Additional Cumulative Receivable
Paid-in Treasury Stock Translation From Sale
Capital (Deficit) Shares Amount Adjustment of Shares
------------- ------------- ------------- ------------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C>
BALANCE, DECEMBER 31, 1993 $ 62,918,000 $ (5,366,000) 0 $ 0
Issuance of common stock on
exercise of stock options 314,000 -- (28,943) (126,000)
Tax benefit from exercise of
stock options 42,000 -- -- --
Retirement of Treasury Stock (125,000) -- 28,943 126,000
Net loss -- (1,979,000) -- --
------------- ------------- ------------- ------------- -------- ---------
BALANCE, DECEMBER 31, 1994 63,149,000 (7,345,000) 0 0
Issuance of common stock
on exercise of stock options 220,000 -- (14,518) (50,000)
Regulation S offering, net 3,444,000 -- -- --
Tax benefit from exercise of
stock options 38,000 -- -- --
Retirement of Treasury Stock (50,000) -- 14,518 50,000
Warrants issued in connection
with debt 90,000 -- -- --
Net income -- 1,047,000 -- --
------------- ------------- ------------- ------------- -------- ---------
BALANCE, DECEMBER 31, 1995 66,891,000 (6,298,000) 0 0
Issuance of common stock
on exercise of stock options 711,000 -- (45,517) (165,000)
Issuance of stock in connection
with acquisitions 34,097,000 -- -- --
Tax benefit from exercise of
stock options 38,000 -- -- --
Retirement of Treasury Stock (164,000) -- 45,517 165,000
Dividend accrued on Preferred Stock -- (88,000) -- -- -- --
Translation adjustment -- -- -- -- $(12,000)
Notes receivable from officers
for sale of shares -- -- -- -- -- $(155,000)
Net loss -- (12,609,000) -- -- -- --
------------- ------------- ------------- ------------- -------- ---------
BALANCE, DECEMBER 31, 1996 $ 101,573,000 $ (18,995,000) 0 $ 0 $(12,000) $(155,000)
============= ============= ============= ============= ======== =========
</TABLE>
See notes to consolidated financial statements.
F-6
<PAGE> 46
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
Year Ended December 31,
1996 1995 1994
------------ ------------ ------------
OPERATING ACTIVITIES
<S> <C> <C> <C>
Net (loss) income $(12,609,000) $ 1,047,000 $ (1,979,000)
Adjustments to reconcile net (loss) income to net cash used in operating
activities:
Depreciation and amortization 3,539,000 3,347,000 3,531,000
Leveraged lease valuation adjustment -- -- 500,000
Deferred income taxes 2,139,000 475,000 (936,000)
Provisions for losses on accounts receivable 606,000 451,000 595,000
Gain on sale of product line (360,000) -- --
Loss on disposal of property, plant and equipment -- 3,000 12,000
Purchased in-process research and
development cost 12,800,000 -- --
Non-cash amounts included in merger
related charges 1,191,000 -- --
Non-cash amounts included in extraordinary loss 476,000 -- --
Other -- -- 7,000
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable (11,279,000) (3,117,000) (4,147,000)
Inventories, other current assets and
recoverable and prepaid income taxes (5,269,000) (1,000) (3,053,000)
Accounts and acceptances payable
and accrued expenses 12,536,000 (5,312,000) 4,183,000
------------ ------------ ------------
NET CASH PROVIDED BY (USED IN)
OPERATING ACTIVITIES 3,770,000 (3,107,000) (1,287,000)
INVESTING ACTIVITIES
Purchase of short-term investments -- -- 1,998,000
Purchase of property, plant and equipment (1,085,000) (709,000) (1,123,000)
Acquisitions, net of cash acquired (4,558,000) (668,000) --
Proceeds from the sale
of property, plant, and equipment -- 19,000 --
Proceeds from sale of product line 500,000 -- --
Proceeds from sale of assets under leveraged lease 487,000 -- --
Start up cost related to the St. Louis
Distribution Center -- -- (171,000)
Notes receivable from officers (155,000) -- --
Net (increase) decrease in other assets (228,000) 116,000 (30,000)
------------ ------------ ------------
NET CASH (USED IN) PROVIDED BY
INVESTING ACTIVITIES $ (5,039,000) $ (1,242,000) $ 674,000
</TABLE>
F-7
<PAGE> 47
GRAHAM-FIELD HEALTH PRODUCTS, INC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS -- (CONTINUED)
<TABLE>
<CAPTION>
Year Ended December 31
1996 1995 1994
------------ ------------ ------------
<S> <C> <C> <C>
FINANCING ACTIVITIES
Proceeds from notes payable to bank
and long-term debt $ 27,310,000 $ 2,054,000 $ 1,673,000
Principal payments on long-term debt
and notes payable (35,576,000) (1,226,000) (1,536,000)
Proceeds on exercise of stock options 550,000 172,000 192,000
Proceeds from issuance of
common stock, net -- 3,471,000 --
Proceeds from issuance of preferred stock
in connection with an acquisition 10,000,000 -- --
NET CASH PROVIDED BY ------------ ------------ ------------
FINANCING ACTIVITIES 2,284,000 4,471,000 329,000
INCREASE (DECREASE) IN CASH AND
CASH EQUIVALENTS 1,015,000 122,000 (284,000)
CASH AND CASH EQUIVALENTS AT
BEGINNING OF YEAR 226,000 104,000 388,000
------------ ------------ ------------
CASH AND CASH EQUIVALENTS AT
END OF YEAR $ 1,241,000 $ 226,000 $ 104,000
============ ============ ============
SUPPLEMENTARY CASH FLOW INFORMATION:
Interest paid $ 2,975,000 $ 2,522,000 $ 2,767,000
============ ============ ============
Income taxes paid $ 187,000 $ 266,000 $ 260,000
============ ============ ============
</TABLE>
See notes to consolidated financial statements.
F-8
<PAGE> 48
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 1996
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business: Graham-Field Health Products, Inc. and its wholly-owned
subsidiaries (the "Company") manufacture, market and distribute medical,
surgical and a broad range of other healthcare products into the home healthcare
and medical/surgical markets through a vast dealer network, consisting of
approximately 18,500 customers, principally hospital, nursing home, physician
and home health care dealers, health care product wholesalers and retailers,
including drug stores, catalog companies, pharmacies, and home-shopping related
businesses in North America. In addition, the Company has increased its presence
in Central and South America, Canada, Mexico, Europe and Asia. The Company
markets and distributes approximately 23,000 products under its own brand names
and under suppliers' names. For the year ended December 31, 1996, approximately
28% of the Company's revenues were derived from products manufactured by the
Company, approximately 18% of the Company's revenues were derived from imported
products and approximately 54% were derived from products purchased from
domestic sources, which includes products purchased from Everest & Jennings
prior to the acquisition.
Principles of Consolidation: The consolidated financial statements include the
accounts of the Company and its subsidiaries, each of which is wholly-owned. All
material intercompany accounts and transactions have been eliminated in
consolidation. Certain amounts in the financial statements of 1996 and all prior
periods have been restated to reflect the Company's acquisition of Medical
Supplies of America, Inc. and subsidiaries. This acquisition was completed on
August 28, 1997 and was recorded on the Company's financial statements as a
"pooling of interests."
Use of Estimates: The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amount of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of income and expenses during the reporting
period. Actual results could differ from those estimates.
Cash Equivalents: The Company considers all highly liquid investments with a
maturity of three months or less when purchased to be cash equivalents.
Inventories: Inventories are valued at the lower of cost or market value. Cost
is determined principally on the standard cost method for manufactured goods and
on the average cost method for other inventories, each of which approximates
actual cost on the first-in, first-out method.
Property, Plant and Equipment: Property, plant and equipment is recorded at
cost, less accumulated depreciation and amortization. Depreciation and
amortization is computed on the straight-line method over the lesser of the
estimated useful lives of the related assets or the lease term, where
appropriate.
Excess of Cost Over Net Assets Acquired: Excess of cost over net assets acquired
is generally amortized on a straight-line basis over 30 to 40 years. The
carrying value of such costs are reviewed by management as to whether the facts
and circumstances indicate that an impairment may have occurred. If this review
indicates that such costs or a portion thereof will not be recoverable, as
determined based on the undiscounted cash flows of the entities acquired over
the remaining amortization period, the carrying value of these costs will be
measured by comparing the fair value of the group of assets acquired to the
carrying value. If fair values are unavailable, the carrying value will be
measured by comparing the carrying values to the discounted cash flows.
F-9
<PAGE> 49
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Impairment of Long-Lived Assets: Effective January 1, 1996, the Company adopted
Statement of Financial Accounting Standards ("SFAS") No. 121, "Accounting for
the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed
Of." This standard establishes the accounting for the impairment of long-lived
assets, certain identifiable intangibles and the excess of cost over net assets
acquired, related to those assets to be held and used in operations, whereby
impairment losses are required to be recorded when indicators of impairment are
present and the undiscounted cash flows estimated to be generated by those
assets are less than the assets' carrying amount. SFAS No. 121 also addresses
the accounting for long-lived assets and certain identifiable intangibles that
are expected to be disposed of. The adoption of SFAS No. 121 did not have a
material effect on the results of operations or financial condition of the
Company.
Revenue Recognition Policy: The Company recognizes revenue when products are
shipped, with appropriate provisions for uncollectible accounts and credits for
returns.
Buy-Back Program: During the first quarter of 1996, the Company's inventory
buy-back program was introduced to provide an outlet for its customers to
eliminate their excess inventory. Under the program, the Company purchases
certain excess inventory from its customers, who in turn place additional
purchase orders with the Company exceeding the value of the excess inventory
purchased. The Company is able to utilize its vast customer base and
distribution network to market and distribute the excess inventory through its
division, National Medical Excess Corp. Substantially all of the medical
products purchased by the Company as part of the inventory buy-back program are
items not generally offered for sale by the Company. Items repurchased by the
Company which are identified as items previously sold by the Company to a
customer have been deminimus based on the Company's experience, and have been
recorded in accordance with the Company's normal revenue recognition policy.
Income Taxes: The Company and its subsidiaries file a consolidated Federal
income tax return. The Company uses the liability method in accounting for
income taxes in accordance with SFAS No. 109. Under this method, deferred tax
assets and liabilities are determined based on differences between financial
reporting and tax bases of assets and liabilities, and are measured using the
enacted tax rates and laws that will be in effect when the differences are
expected to reverse.
Net Loss/Income Per Common Share Information: Net loss per common share for 1996
was computed using the weighted average number of common shares outstanding and
by assuming the accrual of a dividend of 1.5% on both the Series B Cumulative
Convertible Preferred Stock (the "Series B Preferred Stock") and Series C
Cumulative Convertible Preferred Stock (the "Series C Preferred Stock") in the
aggregate amount of $88,000. Conversion of the preferred stock and common
equivalent shares was not assumed since the result would have been antidilutive.
Net income per common share for 1995 was computed using the weighted average
number of common shares and dilutive common equivalent shares outstanding during
the period. Net loss per common share for 1994 was computed using the weighted
average number of common shares outstanding during the period.
In February 1997, the Financial Accounting Standards Board issued SFAS No. 128,
"Earnings Per Share." This standard changes the method of calculating earnings
per share and will be effective for periods ending after December 15, 1997.
Earlier application is not permitted; however, when adopted all prior period
earnings per share data presented will be required to be restated to conform
with the new standard.
F-10
<PAGE> 50
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Employee Stock Options: The Company has a stock option program which is more
fully described in Note 9. The Company accounts for stock option grants in
accordance with APB Opinion No. 25, "Accounting for Stock Issued to Employees."
Under the Company's stock option program, options are granted with an exercise
price equal to the market price of the underlying common stock of the Company on
the date of grant. Accordingly, no compensation expense is recognized in
connection with the grant of stock options.
In October 1995, the Financial Accounting Standards Board issued SFAS No. 123,
"Accounting for Stock-Based Compensation." The new standard defines a fair value
method of accounting for the issuance of stock options and other equity
instruments. Under the fair value method, compensation cost is measured at the
grant date based on the fair value of the award and is recognized over the
service period, which is usually the vesting period. Pursuant to SFAS No. 123,
companies are encouraged, but are not required, to adopt the fair value method
of accounting for employee stock-based transactions. Companies are also
permitted to continue to account for such transactions under Accounting
Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," but
are required to disclose in the financial statement footnotes, proforma net
income and per share amounts as if the Company had applied the new method of
accounting for all grants made during 1995 and 1996. SFAS No. 123 also requires
increased disclosures for stock-based compensation arrangements. Effective
January 1, 1996, the Company adopted the disclosure requirements of SFAS No.
123.
Concentration of Credit Risk: The Company manufactures, markets and distributes
medical, surgical and a broad range of other healthcare products into the home
healthcare and medical/surgical markets through a vast dealer network consisting
of approximately 18,500 customers, principally hospital, nursing home, physician
and home healthcare dealers, healthcare product wholesaler and retailers,
including drug stores, catalog companies, pharmacies and home-shopping related
business in North America. As a result of the acquisition of Everest & Jennings
International Ltd. ("Everest & Jennings") (see Note 2), third party
reimbursement through private or governmental insurance programs and managed
care programs impacts the Company's customers, which affects a portion of the
Company's business. Such impact is not material for 1996. The Company performs
periodic credit evaluations of its customers' financial condition and generally
does not require collateral. Receivables generally are due within 30 to 120
days. Credit losses relating to customers have been consistently within
management's expectations.
Concentration of Sources of Supply: Everest & Jennings' business is heavily
dependent on its maintenance of two key supply contracts. Everest & Jennings
obtains the majority of its homecare wheelchairs and wheelchair components
pursuant to an exclusive supply agreement (the "Exclusive Wheelchair Supply
Agreement") with P.T. Dharma Polimetal ("P.T. Dharma"). The term of this
agreement extends until December 31, 1999, and on each January 1 thereafter
shall be automatically extended for one additional year unless Everest &
Jennings elects not to extend or Everest & Jennings has failed to order at least
50% of the contractually specified minimums and the manufacturer elects to
terminate. If the Exclusive Wheelchair Supply Agreement with P.T. Dharma is
terminated, there can be no assurance that Everest & Jennings will be able to
enter into a suitable supply agreement with another manufacturer. In addition,
Everest & Jennings obtains homecare beds for distribution pursuant to a supply
agreement with Healthtech Products, Inc., a wholly-owned subsidiary of Invacare
Corporation (which is a major competitor of Everest & Jennings), which is
scheduled to expire on October 15, 1997. Although the Company is in the process
of securing alternative sources of supply with other manufacturers, there can be
no assurance that arrangements as favorable as the current supply contract will
be obtainable.
F-11
<PAGE> 51
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Foreign Currency Translation: The financial statements of the Company's foreign
subsidiaries are translated into U.S. dollars in accordance with the provisions
of SFAS No. 52, "Foreign Currency Translation." Assets and liabilities are
translated at year-end exchange rates. Revenues and expenses are translated at
the average exchange rate for each year. The resulting translation adjustments
for each year are recorded as a separate component of stockholders' equity. All
foreign currency transaction gains and losses are included in the determination
of income and are not significant.
2. ACQUISITIONS OF BUSINESSES AND DISPOSAL OF PRODUCT LINE
On November 27, 1996, the Company acquired Everest & Jennings, pursuant to the
terms and provisions of the Amended and Restated Agreement and Plan of Merger
dated as of September 3, 1996 and amended as of October 1, 1996 (the "Merger
Agreement"), by and among the Company, Everest & Jennings, Everest & Jennings
Acquisition Corp., a wholly-owned subsidiary of the Company ("Sub"), and BIL
(Far East Holdings) Limited, a Hong Kong corporation and the majority
stockholder of Everest & Jennings ("BIL"). Under the terms of the Merger
Agreement, Sub was merged with and into Everest & Jennings with Everest &
Jennings continuing as the surviving corporation wholly-owned by the Company
(the "Merger").
In the Merger, each share of Everest & Jennings' common stock, par value $.10
per share (the "Everest & Jennings Common Stock"), other than shares of Everest
& Jennings Common Stock cancelled pursuant to the Merger Agreement, was
converted into the right to receive .35 shares of common stock, par value $.025
per share, of the Company. The Company's common stock was valued at $7.64 per
share, which represents the average closing market price of the Company's common
stock for the period three business days immediately prior to and three business
days immediately after the announcement of the execution of the Merger
Agreement. There were 7,207,689 shares of Everest & Jennings common stock
outstanding on November 26, 1996, which converted into 2,522,691 shares of the
Company's common stock. In addition, in connection with, and at the effective
time of the Merger:
(i) BIL was issued 1,922,242 shares of common stock of the
Company in consideration of the repayment of indebtedness
owing by Everest & Jennings in the amount of $24,989,151 to
Hong Kong and Shanghai Banking Corporation Limited, which
indebtedness (the "HSBC Indebtedness") was guaranteed by BIL.
The proceeds of such stock purchase were contributed by the
Company to Everest & Jennings immediately following the
Merger and used to discharge the HSBC Indebtedness. The
Company's common stock was valued at $7.64 per share, which
represents the average closing market price of the Company's
common stock for the period three business days immediately
prior to and three business days immediately after the
announcement of the execution of the Merger Agreement.
F-12
<PAGE> 52
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
2. ACQUISITIONS OF BUSINESSES AND DISPOSAL OF PRODUCT LINE (CONTINUED)
(ii) The Company issued $61 million stated value of the Series B
Preferred Stock to BIL in exchange for certain indebtedness of
Everest & Jennings owing to BIL and shares of Everest &
Jennings preferred stock owned by BIL. The Series B Preferred
Stock is entitled to a dividend of 1.5% per annum payable
quarterly, votes on an as-converted basis as a single class
with the Company's common stock and the Series C Preferred
Stock (as defined below), is not subject to redemption and is
convertible into shares of the common stock of the Company (x)
at the option of the holder thereof, at a conversion price of
$20 per share (or, in the case of certain dividend payment
defaults, at a conversion price of $15.50 per share), (y) at
the option of the Company, at a conversion price equal to
current trading prices (subject to a minimum conversion price
of $15.50 and a maximum conversion price of $20 per share) and
(z) automatically on the fifth anniversary of the date of
issuance at a conversion price of $15.50 per share. Such
conversion prices are subject to customary antidilution
adjustments. Based on an independent valuation, the fair value
ascribed to the Series B Preferred Stock is $28,200,000.
(iii) BIL was issued $10 million stated value of the Series C
Preferred Stock, the proceeds of which are available
to the Company for general corporate purposes. The Series C
Preferred Stock is entitled to a dividend of 1.5% per annum
payable quarterly, votes on an as-converted basis as a single
class with the Company Common Stock and the Series B Preferred
Stock, is subject to redemption as a whole at the option of
the Company on the fifth anniversary of the date of issuance
at stated value and, if not so redeemed, will be convertible
into shares of the common stock of the Company automatically
on the fifth anniversary of the date of issuance at a
conversion price of $20 per share, subject to customary
antidilution adjustments. Based on an independent valuation,
the fair value ascribed to the Series C Preferred Stock is
$3,400,000.
(iv) Certain indebtedness in the amount of $4 million owing by the
Company to BIL was exchanged for an equal amount of unsecured
subordinated indebtedness of the Company maturing on April 1,
2001 and bearing interest at the effective rate of 7.7% per
annum (the "BIL Note").
The acquisition of Everest & Jennings has been accounted for under the purchase
method of accounting and, accordingly, the operating results of Everest &
Jennings have been included in the Company's consolidated financial statements
since the date of acquisition. The Company allocated $12,800,000 of the purchase
price to purchased in-process research and development projects which have not
reached technological feasibility and have no probable alternative future uses.
The Company expensed the purchased in-process and research development projects
at the date of acquisition. As a result of the acquisition, the Company incurred
$3.0 million of merger related expenses, principally for severance payments, the
write-off of certain unamortized catalog and software costs with no future
value, the accrual of costs to vacate certain of the Company's facilities, and
certain insurance policies. The excess of the aggregate purchase price over the
estimated fair market value of the net assets acquired was approximately $62.2
million, which is being amortized on a straight line basis over 30 years. The
purchase price allocations have been completed on a preliminary basis, subject
to adjustment should new or additional facts about the business become known.
From the date of acquisition, Everest & Jennings contributed approximately
$3,634,000 of revenue for the quarter and year ended December 31, 1996.
F-13
<PAGE> 53
OP GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
2. ACQUISITIONS OF BUSINESSES AND DISPOSAL OF PRODUCT LINE (CONTINUED)
On September 4, 1996, the Company acquired substantially all of the assets of
V.C. Medical Distributors Inc. ("V.C. Medical"), a wholesale distributor of
medical products in Puerto Rico, for a purchase price consisting of $1,703,829
in cash, and the issuance of 32,787 shares of common stock of the Company,
valued at $7.625 per share representing the closing market price of the common
stock of the Company on the last trading day immediately prior to the closing.
In addition, the Company assumed certain liabilities of V.C. Medical in the
amount of $296,721. Under the terms of the transaction, in the event the pre-tax
income of the acquired business equals or exceeds $1,000,000 during the twelve
(12) months following the closing date, an additional $500,000 will be paid to
V.C. Medical. The shares were delivered into escrow, and will be held in escrow
until February 4, 1998, subject to any claims for indemnification for purchase
price adjustments in favor of the Company. The acquisition was accounted for as
a purchase and accordingly, assets and liabilities were recorded at fair value
at the date of acquisition and the results of operations are included subsequent
to that date. The excess of cost over the net assets acquired amounted to
approximately $988,000.
On August 28, 1997, the Company acquired all of the issued and outstanding
shares of the capital stock of Medical Supplies of America, Inc., a Florida
corporation ("Medapex"), pursuant to an Agreement and Plan of Reorganization
(the "Reorganization Agreement") dated August 28, 1997, by and among the
Company, S.E. (Gene) Davis and Vicki Ray (collectively the "Medapex Selling
Stockholders"). In accordance with the terms of the Reorganization Agreement,
Medapex became a wholly-owned subsidiary of the Company and the Medapex Selling
Stockholders received in the aggregate 960,000 shares of Company Common Stock in
exchange for all of the issued and outstanding shares of the capital stock of
Medapex. Pursuant to a Real Estate Sales Agreement dated as of August 28, 1997
(the "Real Estate Sales Agreement") by and between the Company and BBD&M, a
Georgia Limited Partnership and an affiliate of Medapex, the Company acquired
Medapex's principal corporate headquarters and distribution facility in Atlanta,
Georgia for a purchase price consisting of (i) $622,335 payable (x) by the
issuance of 23,156 shares of common stock of the Company and (y) in cash in the
amount of $311,167, and (ii) the assumption of debt in the amount of $477,664.
In connection with the transaction, the Company also entered into a Registration
Rights Agreement dated as of August 28, 1997, pursuant to which the Company
agreed to register for resale the shares of common stock of the Company issued
pursuant to the Reorganization Agreement and the Real Estate Sales Agreement.
Each of the Medapex Selling Stockholders entered into a two-year employment
agreement and non-competition agreement with the Company. Since this
acquisition, which took place on August 28, 1997, is recorded in the Company's
financial statements as a "Pooling of Interests," all prior period
statements have been restated to reflect this transaction.
F-14
<PAGE> 54
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
2. ACQUISITIONS OF BUSINESSES AND DISPOSAL OF PRODUCT LINE (CONTINUED)
The results of operations previously reported by the separate enterprises and
the combined amounts presented in the accompanying consolidated financial
statements are summarized below.
<TABLE>
<CAPTION>
Year Ended December 31,
1996 1995 1994
------------- ------------- -------------
Net revenues:
<S> <C> <C> <C>
Graham-Field $ 127,245,000 $ 100,403,000 $ 94,501,000
Medapex 16,397,000 12,011,000 11,525,000
------------- ------------- -------------
Combined $ 143,642,000 $ 112,414,000 $ 106,026,000
============= ============= =============
Extraordinary loss, net:
Graham-Field $ (736,000) $ -- $ --
Medapex -- -- --
------------- ------------- -------------
Combined $ (736,000) $ -- $ --
============= ============= =============
Net (loss) income:
Graham-Field $ (12,951,000) $ 738,000 $ (2,356,000)
Medapex 342,000 309,000 377,000
------------- ------------- -------------
Combined $ (12,609,000) $ 1,047,000 $ (1,979,000)
============= ============= =============
</TABLE>
The following summary presents unaudited proforma consolidated results of
operations for the years ended December 31, 1996 and 1995 as if the acquisitions
described above occurred at the beginning of each of 1996 and 1995. This
information gives effect to the adjustment of interest expense, income tax
provisions, and to the assumed amortization of fair value adjustments, including
the excess of cost over net assets acquired. Both the 1996 and 1995 pro forma
information includes the write-off of certain purchased in-process research and
development costs of $12,800,000, merger related expenses of $3,000,000, and the
extraordinary item relating to the early retirement of indebtedness applicable
to the Guaranteed Senior Notes. The pro forma net loss per common share has been
calculated by assuming the payment of a dividend of 1.5% on both the Series B
Preferred Stock and Series C Preferred Stock in the aggregate amount of
$1,065,000 for each of the years ended December 31, 1996 and 1995. Conversion of
the preferred stock was not assumed since the result would have been
antidilutive.
<TABLE>
<CAPTION>
Pro-forma
1996 1995
----------------- -------------
<S> <C> <C>
Net Revenues $ 203,919,000 $ 184,364,000
================= =============
Loss Before Extraordinary Item $ <21,088,000> $ (18,692,000)
================= =============
Net loss $ <21,824,000> $ (19,428,000)
================= =============
Common Per Share Data:
Loss Before Extraordinary Item $ (1.13) $ (1.05)
================= =============
Net Loss $ (1.17) $ (1.09)
================= =============
Weighted Average Number of Common Shares
Outstanding 19,632,000 18,755,000
================= =============
</TABLE>
F-15
<PAGE> 55
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
2. ACQUISITIONS OF BUSINESSES AND DISPOSAL OF PRODUCT LINE (CONTINUED)
On March 4, 1996, the Company sold its Gentle Expressions(R) breast pump product
line for $1,000,000 of which $500,000 was paid in cash with the balance in a
secured subordinated promissory note in the aggregate principal amount of
$500,000, payable over 48 months with interest at the prime rate plus one
percent. The Company recorded a gain of $360,000, which is included in other
revenue in the accompanying condensed consolidated statements of operations.
Effective July 1, 1995, the Company acquired substantially all of the assets and
liabilities of National Medical Excess Corp. ("NME"), a distributor of used and
refurbished medical products, including respiratory and durable medical
equipment. The NME acquisition was accounted for under the purchase method of
accounting and accordingly, assets and liabilities were recorded at fair values
at the date of acquisition. Results of operations of NME are included in the
consolidated financial statements of the Company subsequent to that date. The
purchase price, including acquisition expenses, was approximately $723,000 in
cash, plus the assumption of certain liabilities. The excess of cost over the
net assets acquired amounted to approximately $677,000.
3. INVENTORIES
Inventories consist of the following:
<TABLE>
<CAPTION>
December 31
1996 1995
----------- -----------
<S> <C> <C>
Raw materials $ 8,423,000 $ 2,871,000
Work-in-process 4,430,000 1,620,000
Finished goods 35,392,000 26,748,000
----------- -----------
$48,245,000 $31,239,000
=========== ===========
</TABLE>
4. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment consist of the following:
<TABLE>
<CAPTION>
December 31
1996 1995
------------ ------------
<S> <C> <C>
Land and buildings $ 1,462,000 $ 333,000
Equipment 17,490,000 14,833,000
Furniture and fixtures 1,629,000 1,600,000
Leasehold improvements 2,222,000 1,958,000
------------ ------------
22,803,000 18,724,000
Accumulated depreciation and amortization (11,539,000) (10,125,000)
------------ ------------
$ 11,264,000 $ 8,599,000
============ ============
</TABLE>
The Company recorded depreciation and amortization expense on the assets
included in property, plant and equipment of $1,778,000, $1,704,000 and
$1,762,000 for the years ended December 31, 1996, 1995 and 1994, respectively.
F-16
<PAGE> 56
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
5. INVESTMENT IN LEVERAGED LEASE
The Company was the lessor in a leveraged lease agreement entered into in
December 1983, under which helicopters, having an estimated economic life of at
least 22 years, were leased for a term of 16 years. The Company's equity
investment represented 9% of the purchase price; the remaining 91% was furnished
by third-party financing in the form of long-term debt that provided for no
recourse against the Company and was secured by a first lien on the property. At
the end of the lease term, the equipment was to be returned to the Company. The
residual value was estimated to be 57% of the cost. As a result of certain
market conditions and technological advancements, the Company recorded a charge
in the fourth quarter of 1994 of approximately $500,000, which was included in
selling, general and administrative expenses, to reflect the estimated
impairment of the residual value of the helicopters.
In May 1996, the Company liquidated its investment in the leveraged lease
agreement. The cash proceeds of $487,000 approximated the recorded net
investment in the lease at December 31, 1995.
6. NOTES AND ACCEPTANCES PAYABLE
On December 10, 1996, the Company entered into a syndicated three-year senior
secured revolving credit facility (the "Credit Facility") for up to $55 million
of borrowings, including letters of credit and banker's acceptances, arranged by
IBJ Schroder Bank & Trust Company ("IBJ Schroder"), as agent. The proceeds from
the Credit Facility were used to (i) refinance certain existing indebtedness of
the Company, including the indebtedness (a) under the terms of the Note and
Warrant Agreement dated as of March 12, 1992, as amended (the "John Hancock Note
and Warrant Agreement"), with John Hancock Mutual Life Insurance Company ("John
Hancock") (see Note 8), and (b) to The Chase Manhattan Bank, under the line of
credit, (see below); and (ii) to provide for working capital needs of the
Company. Under the terms of the Credit Facility, borrowings bear interest, at
the option of the Company, at IBJ Schroder's prime rate (8.25% at December 31,
1996) or 2.25% above LIBOR, or 1.5% above the IBJ Schroder's bankers' acceptance
rate. The Credit Facility is secured by the Company's inventory and proceeds
thereof.
The Credit Agreement contains certain customary terms and provisions, including
limitations with respect to the incurrence of additional debt, liens,
transactions with affiliates, consolidations, mergers and acquisitions, sales of
assets, dividends and other distributions (other than the payment of dividends
to BIL in accordance with the terms of the Series B and Series C Preferred
Stock). In addition, the Credit Facility contains certain financial covenants,
which become effective as of the end of the fiscal quarter ending June 30, 1997,
and include a cash flow coverage and leverage ratio, and require specified
levels of earnings before interest and taxes.
Pursuant to the terms of the Credit Facility, the Company is prohibited from
declaring, paying or making any dividend or distribution on any shares of the
common stock or preferred stock of the Company (other than dividends or
distributions payable in its stock, or split-ups or reclassifications of its
stock) or apply any of its funds, property or assets to the purchase, redemption
or other retirement of any common or preferred stock, or of any options to
purchase or acquire any such shares of common or preferred stock of the Company.
Notwithstanding the foregoing restrictions, the Company is permitted to pay cash
dividends in any fiscal year in an amount not to exceed the greater of (i) the
amount of dividends due BIL under the terms of the Series B and Series C
Preferred Stock in any fiscal year, or (ii) 12.5% of net income of the Company
on a consolidated basis, provided, that no event of default or default shall
have occurred and be continuing or would exist after giving effect to the
payment of the dividends.
F-17
<PAGE> 57
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
6. NOTES AND ACCEPTANCES PAYABLE (CONTINUED)
At December 31, 1995, the Company had an unsecured line of credit with The Chase
Manhattan Bank available for letters of credit, acceptances and direct
borrowings. The total amount available under the line of credit was $15,000,000.
The line was available for direct borrowings in the amount of up to $5,000,000
and provided for commercial letters of credit and bankers acceptances. This line
of credit expired on December 31, 1996; however, amounts outstanding at that
date for bankers acceptances and letters of credit mature through March 31,
1997.
At December 31, 1996, the Company had aggregate direct borrowings under both
banks' facilities of $13,985,000 and acceptances payable of $19,800,000. The
weighted average interest rate on the amounts outstanding as of December 31,
1996 was 7.65%. Open letters of credit at December 31, 1996 were $1,568,000
relating to trade credit and $6.0 million for other requirements.
At December 31, 1995, the Company had direct borrowings of $2,100,000 and
$5,000,000 utilized under acceptances payable. The weighted average interest
rate on the amounts outstanding as of December 31, 1995 was 8.6%.
7. LONG-TERM DEBT
Long-term debt consists of the following:
<TABLE>
<CAPTION>
December 31,
1996 1995
---------- ----------
<S> <C> <C>
Note payable to BIL (a) $4,000,000 --
Notes payable to International Business
Machines Corp. ("IBM") (b) 1,019,000 $1,550,000
Capital lease obligations (c) 1,344,000 --
Other (d) 2,188,000 490,000
---------- ----------
8,551,000 2,040,000
Less current maturities 2,016,000 578,000
---------- ----------
$6,535,000 $1,462,000
========== ==========
</TABLE>
(a) On July 18, 1996, an affiliate of BIL provided the Company with a loan
in the amount of $4,000,000, at an effective interest rate of 8.8%. The
loan was used to fund the acquisition of V.C. Medical and for general
corporate purposes. In connection with the acquisition of Everest &
Jennings, the indebtedness owing by the Company to BIL was exchanged
for the BIL Note. Under the terms of the BIL Note, the Company has the
right to reduce the principal amount of the BIL Note in the event
punitive damages are awarded against the Company or any of its
subsidiaries which relate to any existing product liability claims of
Everest & Jennings and/or its subsidiaries involving a death prior to
September 3, 1996.
F-18
<PAGE> 58
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
7. LONG-TERM DEBT (CONTINUED)
(b) In connection with the development of the Company's St. Louis
Distribution Center, the Company entered into an agreement with IBM to
provide the computer hardware and software, and all necessary
warehousing machinery and equipment including installation thereof.
This project was primarily financed through IBM by the issuance of the
Company's unsecured notes which corresponded to various components of
the project. The unsecured notes mature through October 2000, with
interest rates ranging from 7.68% to 11.53%.
(c) At December 31, 1996, the Company is obligated under certain lease
agreements for equipment which have been accounted for as capital
leases. The capital leases were acquired in connection with the
acquisition of Everest & Jennings. Future minimum payments in the
aggregate are as follows:
<TABLE>
<CAPTION>
Year Ended December 31 Amount
-----------
<S> <C> <C>
1997 $ 954,000
1998 476,000
1999 13,000
-----------
Total 1,443,000
Less amounts representing interest 99,000
-----------
Present value of future minimum
lease payments $1,344,000
===========
</TABLE>
The net book value of assets held under capital lease obligations
amounted to $424,000 at December 31, 1996.
(d) Other long-term debt consists primarily of a mortgage payable in the
amount of $1,100,000 due in monthly installments of $22,906 through
November 1998, with a final payment of approximately $570,000 due on
November 30, 1998, and bearing interest at prime plus one-half percent.
In addition, the Company has a credit facility for its Mexican
subsidiary, of which $500,000 was outstanding as of December 31, 1996.
Borrowings under the credit facility bear interest at approximately
13%. The Mexican borrowings are secured by the assets of the Mexican
subsidiary. The borrowings are payable in semi-annual installments of
$100,000 through 1999. Also, the Company assumed debt in the amount of
$478,000 pursuant to its acquisition of Medapex's principal
headquarters in Atlanta. This debt is in the form of a note payable
(the "Note") to the local bank with a remaining term of approximately
seven (7) years. The Note, which is collateralized by the principal
headquarters, requires the payment of interest at 72% of the current
prime rate (8.5% as of the date which the Company assumed the Note).
Since this acquisition, which took place on August 28, 1997, is
recorded in the Company's financial statements as a "pooling of
interests" all prior period statements have been restated to reflect
this transaction.
F-19
<PAGE> 59
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
7. LONG-TERM DEBT (CONTINUED)
The scheduled maturities of the long-term debt obligations, excluding the
present value of minimum payments on capital lease obligations, are as follows:
<TABLE>
<CAPTION>
Year Ended December 31 Amount
---------------------- ------------
<S> <C> <C>
1997 $ 1,166,000
1998 1,484,000
1999 192,000
2000 86,000
2001 4,279,000
-----------
$7,207,000
===========
</TABLE>
8. GUARANTEED SENIOR NOTES
On March 12, 1992, under the John Hancock Note and Warrant Agreement, the
Company privately sold at par to John Hancock its 8.28% Guaranteed Senior Notes
due February 29, 2000 (the "Guaranteed Senior Notes"), in the aggregate
principal amount of $20,000,000 (the "John Hancock Indebtedness"), and five-year
warrants to purchase 125,000 shares of the common stock of the Company at an
exercise price of $12 per share. During 1993, the John Hancock Note and Warrant
Agreement was amended to modify the terms of certain financial covenants and the
terms of the warrants issued to John Hancock. The amendment to the John Hancock
Note and Warrant Agreement provided for, among other things, an increase in the
number of shares available for issuance under the warrants from 125,000 shares
to 250,000 shares of the common stock of the Company (the "Initial Warrants"), a
reduction in the exercise price of the warrants from $12.00 to $5.50 per share,
and an extension of the expiration date of the warrants to February 29, 2000.
The Initial Warrants, which were revalued as of the date of amendment, have been
valued at $365,000, and are being amortized as additional interest over the
remaining term of the debt. At December 30, 1994, the John Hancock Note and
Warrant Agreement was amended to modify the terms of certain financial
covenants. In connection with the amendment, the Company issued to John Hancock
additional warrants to purchase 90,000 shares of the common stock of the Company
(the "Additional Warrants") at an exercise price of $5.25 per share, with an
expiration date of February 29, 2000. The Additional Warrants were valued at
$90,000 and were amortized as additional interest over the remaining term of the
debt. As a result of the Company's offshore private placement of 1,071,655
shares of common stock completed in September 1995, additional warrants to
purchase 5,336 shares of the common stock of the Company were issued to John
Hancock. In connection with the Company's offshore private placement, the
exercise prices of the warrants were adjusted from $5.50 per share to $5.42 per
share with respect to the Initial Warrants and from $5.25 per share to $5.17 per
share with respect to the Additional Warrants.
In connection with the issuance and amendments to the Guaranteed Senior Notes,
issuance costs of approximately $506,000, net of accumulated amortization of
$331,000, were included in other assets at December 31, 1995. Such costs were
amortized over the term of the Guaranteed Senior Notes.
During December 1996, the Company retired the John Hancock Indebtedness with
proceeds from the Company's Credit Facility with IBJ Schroder. In connection
with the early retirement of the John Hancock Indebtedness, the Company incurred
charges relating to the "make-whole" payment and the write-off of all
unamortized financing costs associated with the John Hancock Note and Warrant
Agreement. The charges amounted to $736,000 (net of a tax benefit of $383,000),
and are reported as an extraordinary item in the accompanying consolidated
statements of operations.
F-20
<PAGE> 60
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
9. STOCKHOLDERS' EQUITY
On March 23, 1989, the Company declared, and on July 21, 1989 the stockholders
approved, a dividend distribution to stockholders of record on July 21, 1989 of
one right for each outstanding share of the Company's common stock pursuant to a
Rights Agreement dated as of July 21, 1989, between the Company and American
Stock Transfer & Trust Company, as Rights Agent (the "1989 Rights Agreement").
On September 3, 1996, immediately prior to the execution of the Merger
Agreement, the Company entered into an amendment to the 1989 Rights Agreement,
with the effect of exempting the events and transactions contemplated by the
Merger Agreement and the Amended and Restated Stockholder Agreement dated as of
September 3, 1996, as amended on September 19, 1996, by and among the Company
and Irwin Selinger (the "Stockholder Agreement"), from the 1989 Rights
Agreement. In addition, on that date the rights previously issued under the 1989
Rights Agreement were called for redemption on September 17, 1996.
On September 3, 1996, the Company also entered into a new Rights Agreement with
American Stock Transfer & Trust Company, as Rights Agent (the "1996 Rights
Agreement"). As contemplated by the 1996 Rights Agreement, the Company's Board
of Directors declared a dividend of one new preferred share purchase right (a
"Right") for each outstanding share of the common stock of the Company
outstanding on September 17, 1996. Each Right entitles the holder thereof to
purchase from the Company one one-hundredth of a share of Series A Junior
Participating Preferred Stock, par value $.01 per share, of the Company (the
"Preferred Shares") at a price of $35.00 per one one-hundredth of a Preferred
Share, subject to adjustment as provided in the 1996 Rights Agreement.
Until the earlier to occur of (i) 10 days following a public announcement that a
person or group of affiliated or associated persons have acquired (an "Acquiring
Person") beneficial ownership of 15% or more of the outstanding shares of
capital stock of the Company entitled generally to vote in the election of
directors ("Voting Shares") or (ii) 10 business days (or such later date as may
be determined by action of the Board of Directors prior to such time as any
person or group of affiliated persons becomes an Acquiring Person) following the
commencement of, or announcement of an intention to make, a tender offer or
exchange offer the consummation of which would result in a person or group
becoming an Acquiring Person (the earlier of such dates being called the
"Distribution Date"), the Rights will be evidenced, with respect to any of the
common stock certificates outstanding as of the record date, by such common
stock certificate. Notwithstanding the foregoing, BIL will not be an Acquiring
Person by virtue of its ownership of any Voting Shares acquired in accordance
with the Merger Agreement or the Stockholder Agreement (the "BIL Voting
Shares"), but BIL will become an Acquiring Person if it acquires any Voting
Shares other than BIL Voting Shares or shares distributed generally to the
holders of any series or class of capital stock of the Company. In addition, the
1996 Rights Agreement contains provisions exempting the Merger and the other
events and transactions contemplated by the Merger Agreement and the Stockholder
Agreement from the 1996 Rights Agreement.
The 1996 Rights Agreement provides that, until the Distribution Date (or earlier
redemption or expiration of the Rights), the Rights will be transferred with and
only with the common stock of the Company. The Rights are not exercisable until
the Distribution Date. The Rights will expire on September 3, 2006.
F-21
<PAGE> 61
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
9. STOCKHOLDERS' EQUITY (CONTINUED)
Preferred Shares purchasable upon exercise of the Rights will not be redeemable.
Each Preferred Share will be entitled to a minimum preferential quarterly
dividend payment of $1 per share but will be entitled to an aggregate dividend
of 100 times the dividend declared per share of common stock of the Company. In
the event of liquidation, the holders of the Preferred Shares will be entitled
to a minimum preferential liquidation payment of $100 per share but will be
entitled to an aggregate payment of 100 times the payment made per share of
common stock. Each Preferred Share will have 100 votes, voting together with the
shares of common stock of the Company. In the event of any merger, consolidation
or other transaction in which the common stock of the Company is exchanged, each
Preferred Share will be entitled to receive 100 times the amount received per
share of common stock of the Company. The Rights are protected by customary
antidilution provisions. Because of the nature of the Preferred Shares'
dividend, liquidation and voting rights, the value of the one one-hundredth
interest in a Preferred Share purchasable upon exercise of each Right should
approximate the value of one share of common stock of the Company.
In the event the Company is acquired in a merger or other business combination
transaction or 50% or more of its consolidated assets or earning power are sold
after a person or group has become an Acquiring Person, proper provision will be
made so that each holder of a Right will thereafter have the right to receive,
upon the exercise thereof at the then current exercise price of the Right, that
number of shares of common stock of the acquiring company which at the time of
such transaction will have a market value of two times the exercise price of the
Right.
In the event that any person or group of affiliated or associated persons
becomes an Acquiring Person, the 1996 Rights Agreement provides that proper
provision shall be made so that each holder of a Right, other than Rights
beneficially owned by the Acquiring Person (which will thereafter be void), will
thereafter have the right to receive (subject to adjustment) upon exercise that
number of shares of common stock of the Company having a market value of two
times the exercise price of the Right. At any time after any person or group
becomes an Acquiring Person and prior to the acquisition by such person or group
of 50% or more of the outstanding Voting Shares, the Board of Directors of the
Company may exchange the Rights (other than Rights owned by such person or
group, which will have become void), in whole or in part, at an exchange ratio
of one share of common stock, or one one-hundredth of a Preferred Share (or of a
share of a class or series of the Company's preferred stock having equivalent
rights, preferences and privileges), per Right (subject to adjustment).
At any time prior to a person or group of affiliated or associated persons
becoming an Acquiring Person, the Board of Directors of the Company may redeem
the Rights in whole, but not in part, at a price of $.01 per Right (the
"Redemption Price"). The redemption of the Rights may be made effective at such
time on such basis with such conditions as the Board of Directors in its sole
discretion may establish. Immediately upon any redemption of the Rights in
accordance with this paragraph, the right to exercise the Rights will terminate
and the only right of the holder of the Rights will be to receive the Redemption
Price.
F-22
<PAGE> 62
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
9. STOCKHOLDERS' EQUITY (CONTINUED)
The terms of the Rights may be amended by the Board of Directors of the Company
without the consent of the holders of the Rights, including an amendment to (a)
lower certain thresholds described above to not less than the greater of (i) any
percentage greater than the largest percentage of the outstanding Voting Shares
then known to the Company to be beneficially owned by any person or group of
affiliated or associated persons and (ii) 10%, (b) fix a Final Expiration Date
later than September 3, 2006, or (c) reduce the Redemption Price, (d) increase
the Purchase Price, except that from and after such time as any person or group
of affiliated or associated persons becomes an Acquiring Person no such
amendment may adversely affect the interests of the holders of the Rights (other
than the Acquiring Person and its affiliates and associates).
As long as the Rights are attached to the common stock of the Company, the
Company will issue one Right with each new share of common stock so that all
such shares will have Rights attached. The Company's Board of Directors has
reserved for issuance 300,000 Preferred Shares upon exercise of the Rights.
On November 27, 1996, in connection with the acquisition of Everest & Jennings
(see Note 2), the Company issued $61 million stated value of Series B Preferred
Stock and $10 million stated value of Series C Preferred Stock to BIL, and
issued an aggregate of 4,444,933 shares of the Company's common stock. The
Series B Preferred Stock is entitled to a dividend of 1.5% per annum payable
quarterly, votes on an as-converted basis as a single class with the common
stock of the Company and the Series C Preferred Stock, is not subject to
redemption and is convertible into shares of the common stock of the Company (x)
at the option of the holder thereof, at a conversion price of $20 per share (or,
in the case of certain dividend payment defaults, at a conversion price of
$15.50 per share), (y) at the option of the Company, at a conversion price equal
to current trading prices (subject to a minimum conversion price of $15.50 and a
maximum conversion price of $20 per share) and (z) automatically on the fifth
anniversary of the date of issuance at a conversion price of $15.50 per share.
Such conversion prices are subject to customary antidilution adjustments.
The Series C Preferred Stock is entitled to a dividend of 1.5% per annum payable
quarterly, votes on an as-converted basis as a single class with the common
stock of Company and the Series B Preferred Stock, is subject to redemption as a
whole at the option of the Company on the fifth anniversary of the date of
issuance at stated value and, if not so redeemed, will be convertible into
shares of the common stock of the Company automatically on the fifth anniversary
of the date of issuance at a conversion price of $20 per share, subject to
customary antidilution adjustments.
In September 1995, the Company completed an offshore private placement of
1,071,655 shares of the common stock of the Company with various European
institutional investors. The net proceeds of $3,471,000 realized from the
offering were used for general corporate purposes.
On November 27, 1996, the Company amended its certificate of incorporation to
provide for, among other things, an increase in the number of authorized shares
of common stock from 40,000,000 to 60,000,000 shares.
On September 4, 1996, the Company acquired substantially all of the assets of
V.C. Medical, in consideration of the issuance of 32,787 shares of the common
stock.
F-23
<PAGE> 63
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
9. STOCKHOLDERS' EQUITY (CONTINUED)
Under the Company's stock option program, the Company is authorized to grant
incentive stock options, non-qualified stock options, stock appreciation rights,
restricted stock grants and restored options. Incentive stock options may be
granted at not less than 100% (110% for owners of more than 10% of the Company's
outstanding common stock) of the fair market value of the Company's common stock
at the date of grant. Stock options outstanding under the program generally vest
and are exercisable at a rate of 50% per annum. Effective as of December 21,
1995, directors' options to purchase 10,000 shares of the common stock of the
Company are granted to eligible directors each January 2, at an exercise price
equal to the fair market value of the common stock at the date of grant.
Directors' options are exercisable one-third each year for three years, and have
a term of ten years. Incentive and non-qualified options expire five years from
the date of grant.
In 1992, the Company amended its stock option program to increase the maximum
number of shares available under the program from 900,000 to 1,500,000. In 1995,
the Company amended its stock option program to increase the maximum number of
shares available under the program from 1,500,000 to 2,100,000. In 1996, the
plan was further amended to increase the maximum number of shares available from
2,100,000 to 3,000,000.
During 1996, 1995 and 1994, officers of the Company surrendered 45,517, 14,518
and 28,943 shares, respectively, of the Company's common stock with a fair
market value of $165,000, $50,000 and $126,000, respectively, in satisfaction of
the exercise price of stock options to purchase 50,000, 25,000 and 58,187
shares, respectively, of common stock of the Company. The shares received in
satisfaction of the exercise price of stock options were recorded as treasury
stock and were retired on a quarterly basis as authorized by the Board of
Directors. Accordingly all such shares have been restored as authorized and
unissued shares of common stock.
The Company has elected to comply with Accounting Principles Board Opinion No.
25, "Accounting for Stock Issued to Employees" (APB 25) and related
interpretations in accounting for its employee stock options because the
alternate fair value accounting provided for under FASB Statement No. 123,
"Accounting for Stock-Based Compensation," requires use of option valuation
models which were not developed for use in valuing employee stock options. Under
APB 25, no compensation expense is recognized in connection with the grant of
stock options under the Company's stock option program.
In accordance with FASB Statement No. 123, pro forma information regarding net
loss and loss per common share has been determined as if the Company had
accounted for its employee stock options under the fair value method of that
Statement. The fair value for these options was estimated at the date of grant
using a Black-Scholes option pricing model with the following weighted average
assumptions for 1996 and 1995, respectively: risk-free interest rate of 6.5%;
dividend yields on the preferred stock of 1.5%, volatility factors of the
expected market price of the Company's common stock of .41 and .42; and a
weighted-average expected life of the option of 3.2 years.
The Black-Scholes option valuation model was developed for use in estimating the
fair value of traded options which have no vesting restrictions and are fully
transferable. In addition, option valuation models require the input of highly
subjective assumptions including the expected stock price volatility. In
management's opinion, the existing models do not necessarily provide a reliable
single measure of the fair value of its employee stock options due to changes in
subjective input assumptions which may materially affect the fair value
estimate, and because the Company's employee stock options have characteristics
significantly different from those of traded options.
F-24
<PAGE> 64
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
9. STOCKHOLDERS' EQUITY (CONTINUED)
For purposes of pro forma disclosures, the estimated fair value of the options
is amortized to expense over the options' vesting period. The Company's
pro-forma information is as follows:
<TABLE>
<CAPTION>
1996 1995
------------ ------------
<S> <C> <C>
Pro forma net (loss) income $(13,098,000) $ 953,000
Pro forma net (loss) income per share: $ ( .85) $ .07
</TABLE>
FASB Statement No. 123 is applicable only to options granted subsequent to
December 31, 1994. Accordingly, the pro forma effect will not be fully reflected
until 1997.
Information with respect to options during the years ended December 31, 1996 and
1995 under FASB Statement No. 123 and for the year ended December 31, 1994 under
APB 25 is as follows:
<TABLE>
<CAPTION>
1996 1995 1994
-------------- -------------- ---------
Weighted Weighted
Average Average Option
Options Exercise Price Options Exercise Price Options Exercise Price
--------- ----- -------- ---------- -------- --------------
<S> <C> <C> <C> <C> <C> <C>
Options outstanding -
beginning of year 912,645 $5.49 818,379 $ 6.10 824,886 $2.00 - $11.75
Options granted:
Incentive options 699,121 6.45 257,432 3.47 144,278 $4.125 - $5.913
Directors' options 90,000 3.25 91,852 3.65 50,000 $4.75 - $5.375
Non-qualified options 91,764 6.02 -- 29,165 $4.125 - $5.913
Options exercised (103,255) (3.83) (86,500) (2.58) (149,250) $2.00 - $3.00
Options cancelled
and expired (47,100) (4.87) (168,518) (5.79) (80,700) $2.00 - $11.75
--------- ----- -------- ---------- --------
Options outstanding -
end of year 1,643,175 $5.77 912,645 $ 5.49 818,379 $2.00 - $11.75
========= ===== ======== ========== ========
Options exercisable at
end of year 582,244 $5.45 483,929 $ 4.95 507,686
========= ===== ======== ========== ========
Weighted average fair
value of options granted
during the year $ 2.10 $ 1.20
========= ========
</TABLE>
F-25
<PAGE> 65
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
9. STOCKHOLDERS' EQUITY (CONTINUED)
Exercise prices for options outstanding as of December 31, 1996 were as follows:
<TABLE>
<CAPTION>
Number of Range of Exercise Prices
Options ------------------------
-----------
<S> <C> <C>
20,000 $2.00 - $2.99
409,535 3.00 - 3.99
198,922 4.00 - 4.99
194,400 5.00 - 5.99
44,000 6.00 - 6.99
725,050 7.00 - 7.99
51,268 Over 8.00
-----------
1,643,175
===========
</TABLE>
The weighted average remaining contractual life of those options is 5 years.
Shares of common stock reserved for future issuance as of December 31, 1996 are
as follows:
<TABLE>
<CAPTION>
Number of Shares
----------------
<S> <C>
Stock options 2,240,163
Warrants issued to John Hancock 345,336
Series B Preferred Stock 3,935,483
Series C Preferred Stock 500,000
---------
7,020,982
=========
</TABLE>
The exercise of non-qualified stock options and disqualifying dispositions of
incentive stock options resulted in Federal and state income tax benefits to the
Company equal to the difference between the market price at the date of exercise
or sale of stock and the exercise price of the option. Accordingly, during 1996,
1995 and 1994, approximately $38,000, $38,000 and $42,000, respectively, was
credited to additional paid in capital.
10. INCOME TAXES
At December 31, 1996, the Company had aggregate net operating loss carryforwards
of approximately $22,745,000 for income tax purposes which expire at various
dates from 2008 to 2010, of which approximately $20,480,000 were acquired in
connection with the Everest & Jennings acquisition and expire primarily in 2010
and are limited as to use in any particular year. In addition, at December 31,
1996, the Company had approximately $890,000 (net of a 35% reduction of
investment tax credits as a result of the Tax Reform Act of 1986) of investment,
research and development, jobs tax and AMT credits, for income tax purposes
which expire primarily in 1999, and which includes alternative minimum tax
credits of $500,000 which have no expiration date. The Company has provided a
valuation allowance in the fourth quarter of 1996 amounting to approximately
$400,000, since the credits are available only through the expiration dates, and
only after the utilization of available net operating loss carryforwards. In
1995, the Company recorded deferred State tax benefits previously not recognized
as a component of the net operating loss carryforwards.
F-26
<PAGE> 66
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
10. INCOME TAXES (CONTINUED)
For financial reporting purposes, due to prior years losses of Everest &
Jennings, and SRLY limitations, a full valuation allowance of approximately
$14,494,000 has been recognized in the purchase of Everest & Jennings to offset
the net deferred tax assets related to the acquired tax attributes. If realized,
the tax benefit for those items will be recorded as a reduction to the excess
cost over net assets acquired. In addition, the Company has provided an
additional valuation allowance of $600,000 against a portion of its remaining
net deferred tax asset at December 31, 1996 due to the recent acquisition of
Everest & Jennings. The amount of the remaining deferred tax asset considered
realizable could be reduced in the near term if estimates of future taxable
income during the carryforward period are reduced.
Deferred income taxes reflect the net tax effects of temporary differences
between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Significant components of
the Company's deferred tax assets and liabilities as of December 31, 1996 and
1995 are as follows:
<TABLE>
<CAPTION>
1996 1995
------------ -----------
<S> <C> <C>
Deferred Tax Assets:
Net operating loss carryforwards $ 7,893,000 $ 3,043,000
Tax credits 890,000 744,000
Accounts receivable allowances 2,600,000 723,000
Inventory related 2,575,000 1,226,000
Deferred rent 382,000 403,000
Other reserves and accrued items 4,765,000 77,000
------------ -----------
19,105,000 6,216,000
Valuation allowance for deferred assets (15,549,000) (55,000)
------------ -----------
Total deferred tax assets 3,556,000 6,161,000
------------ -----------
Deferred Tax Liabilities:
Tax in excess of book depreciation 1,696,000 1,713,000
Leveraged lease -- 506,000
Prepaid expenses 254,000 250,000
Amortization of intangibles 668,000 477,000
Other -- 131,000
------------ -----------
Total deferred tax liabilities 2,618,000 3,077,000
------------ -----------
Net deferred tax assets $ 938,000 $ 3,084,000
============ ===========
</TABLE>
F-27
<PAGE> 67
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
10. INCOME TAXES (CONTINUED)
Significant components of the provision (benefit) for income taxes are as
follows:
<TABLE>
<CAPTION>
1996 1995 1994
---------- --------- ---------
<S> <C> <C> <C>
Current:
Federal $ 328,000 $ 129,000 $ 177,000
State and local 86,000 71,000 44,000
Foreign 9,000 -- --
---------- --------- ---------
423,000 200,000 221,000
Deferred Federal and state 2,495,000 494,000 (956,000)
---------- --------- ---------
$2,918,000 $ 694,000 $(735,000)
========== ========= =========
</TABLE>
The following is a reconciliation of income tax computed at the Federal
statutory rate to the provision for taxes:
<TABLE>
<CAPTION>
1996 1995 1994
-------------- -------------- ---------
Amount Percent Amount Percent Amount Percent
----------- --------- --------- --------- --------- ---------
<S> <C> <C> <C> <C> <C> <C>
Tax expense (benefit)
computed at
statutory rate $(3,045,000) (34%) $ 592,000 34% $(923,000) (34%)
Expenses not
deductible for
income tax purposes:
Amortization of
excess of cost over
net assets acquired 276,000 3% 286,000 16% 239,000 9%
In-process R&D
costs 4,352,000 49% -- -- -- --
Other 32,000 -- 7,000 1% 43,000 1%
State tax expense
(benefit), net of
Federal benefit 303,000 3% 121,000 7% (94,000) (3%)
Previously
unrecognized
State tax benefits -- -- (312,000) (18%) -- --
Valuation allowance
on net deferred tax
assets 1,000,000 11% -- -- -- --
----------- --------- --------- --------- --------- ---------
$ 2,918,000 32% $ 694,000 40% $(735,000) (27%)
=========== ========= ========= ========= ========= =========
</TABLE>
F-28
<PAGE> 68
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
11. EMPLOYEE BENEFIT PLANS
The Company has a non-contributory defined benefit pension plan covering
employees of its subsidiary, Everest & Jennings Inc. and two non-contributory
defined benefit pension plans for the non-bargaining unit salaried employees
("Salaried Plan") and employees subject to collective bargaining agreements
("Hourly Plan") at its Smith & Davis subsidiary. Effective May 1, 1991, benefits
accruing under the Everest & Jennings, Inc. Pension Plan were frozen. During
1991, Everest & Jennings froze the Hourly Plan and purchased participating
annuity contracts to provide for accumulated and projected benefit obligations.
Everest & Jennings also froze the Salaried Plan effective as of January 1, 1993.
Accordingly, no pension cost has been reflected in the accompanying statement of
operations.
The following table sets forth the status of these plans and the amounts
recognized in the Company's consolidated financial statements.
<TABLE>
<CAPTION>
1996
-----------
<S> <C>
Actuarial present value of benefit obligations:
Vested benefit obligation $17,567,000
-----------
Accumulated benefit obligation $17,567,000
-----------
Projected benefit obligation for services rendered to date $17,567,000
Plan assets at fair value, primarily listed stocks, bonds,
investment funds and annuity contracts 14,746,000
-----------
Projected benefit obligation in excess of plan assets 2,821,000
Unrecognized transition amount --
Unrecognized loss from change in discount rate --
-----------
Pension liability (current portion of $1,069,000) $ 2,821,000
===========
</TABLE>
The following assumptions were used to determine the projected benefit
obligations and plan assets:
<TABLE>
<CAPTION>
Everest & Jennings, Inc. Smith & Davis
Plan Plans
---- ----
1996 1996
---- ----
<S> <C> <C>
Weighted-average discount rate 7.5% 7.5%
Expected long-term rate of return on assets 9.0% 9.0%
</TABLE>
No long-term rate for compensation increases were assumed as all participants
are inactive and the plans are frozen.
The Company also sponsors three 401(k) Savings and Investment Plans. One plan
covers all full-time employees of the Company's wholly-owned subsidiary, Everest
& Jennings, the other plan covers all full time employees of the Company's
wholly-owned subsidiary, Medapex, and the last plan covers the remaining
employees of the Company. The Company does not contribute to its plan and the
Everest & Jennings' plan. The Medapex plan matches 25% of the employees
contribution up to a maximum contribution of 6% of the employee's salary.
Amounts expensed for the Medapex plan for the fiscal years 1996, 1995 and 1994
were immaterial.
F-29
<PAGE> 69
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
12. DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS
The following methods and assumptions were used to estimate the fair value of
each class of financial instruments as of December 31, 1996 and 1995, for which
it is practicable to estimate that value:
Cash and cash equivalents: The carrying amounts reported in the accompanying
balance sheets approximate fair value.
Notes and acceptances payable: The carrying amounts of the Company's borrowings
under its credit facility approximate their fair value.
Long-term debt: The fair values of the Company's long-term debt are estimated
using discounted cash flow analyses, based on the Company's incremental
borrowing rates for similar types of borrowing arrangements. At December 31,
1996 and 1995, the carrying amount reported approximates fair value.
Investment in leveraged lease: The carrying amounts reported in the accompanying
balance sheet for 1995 approximate fair value. Fair value is determined based on
the current value of the underlying assets.
Guaranteed Senior Notes: The fair value of the Company's Guaranteed Senior Notes
is estimated using a discounted cash flow analysis based on current rates
offered to the Company for debt of the same remaining maturity. At December 31,
1995, the fair value of such debt was approximately $19,200,000.
13. COMMITMENTS AND CONTINGENCIES
OPERATING LEASES
The Company is a party to a number of noncancellable lease agreements for
warehouse space, office space and machinery and equipment rental. As of December
31, 1996 the agreements extend for various periods ranging from 1 to 11 years
and certain leases contain renewal options. Certain leases provide for payment
of real estate taxes and include escalation clauses.
For those leases which have escalation clauses, the Company has recorded rent
expense on a straight-line basis. At December 31, 1996 and 1995, $933,000 and
$984,000, respectively, of rent expense was accrued in excess of rental payments
made by the Company.
As of December 31, 1996, minimal annual rental payments under all noncancellable
operating leases are as follows:
<TABLE>
<CAPTION>
Year Ended December 31:
-----------------------
<S> <C>
1997 $ 3,174,000
1998 3,132,000
1999 3,007,000
2000 2,806,000
2001 2,788,000
Thereafter 11,230,000
------------
$26,137,000
============
</TABLE>
Rent expense for the years ended December 31, 1996, 1995 and 1994 approximated
$2,805,000, $2,400,000, and $2,549,000, respectively.
F-30
<PAGE> 70
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
13. COMMITMENTS AND CONTINGENCIES (CONTINUED)
LEGAL PROCEEDINGS
On June 19, 1996, a class action lawsuit was filed on behalf of all stockholders
of Everest & Jennings (other than the named defendants) in the Delaware Court of
Chancery, following announcement on June 17, 1996 of the original agreement in
principle between Everest & Jennings and the Company. The class action names as
defendants the Company, Everest & Jennings, Everest & Jennings' directors, and
BIL. The class action challenges the transactions contemplated by the original
agreement in principle, alleging, among other things, that (i) such transactions
were an attempt to eliminate the public stockholders of Everest & Jennings at an
unfair price, (ii) BIL will receive more value for its holdings in Everest &
Jennings than its minority stockholders, (iii) the public stockholders will not
be adequately compensated for the potential earnings of Everest & Jennings, (iv)
BIL and the directors of Everest & Jennings breached or aided and abetted the
breach of fiduciary duties owed to the stockholders (other than the defendants)
by not exercising independent business judgment and having conflicts of
interest, and (v) the Company aided and abetted and induced breaches of
fiduciary duties by other defendants by offering incentives to members of
management, either in the form of continued employment or monetary compensation
and perquisites, in exchange for their approval of the merger. The class action
seeks to rescind the merger or an award of rescissionary damages if it cannot be
set aside, and also prays for an award of compensatory damages. The Company
believes that it has valid defenses to the complaint's allegations of
wrongdoing, and intends to vigorously defend the lawsuit.
On May 21, 1996, the Company was sued by Minnesota Mining & Manufacturing
Company ("3M") in a claim purportedly arising under federal, state and common
law trademark, false advertising, and unfair competition laws, as well as for
breach of, and interference with, contracts. 3M alleges that the Company is
selling 3M products in violation of federal and state law, and seeks monetary
damages in an unspecified amount, as well as injunctive relief against the
Company's continued sale of 3M products. The claim was filed in the Southern
District of New York. The Company vigorously denies the allegations of 3M's
complaint, and has filed an answer denying the allegations of wrongdoing and
asserting affirmative defenses. In addition, the Company has asserted
counterclaims against 3M under federal antitrust laws, as well as an unfair
competition claim. On October 16, 1996, 3M moved to dismiss the Company's
antitrust counterclaims. Briefing of the motion has been completed and the
parties are awaiting a decision. 3M has proposed a settlement of all claims
pursuant to which the Company would, among other things, agree to restrict its
purchases of 3M products to certain authorized 3M dealers, and make a payment of
no more than $400,000. Although settlement discussions are ongoing, it is not
possible to predict the outcome of such discussions.
Everest & Jennings and its subsidiaries are parties to certain lawsuits and
proceedings as described below (the "Everest & Jennings Proceedings"). Under the
terms of the Stockholder Agreement, BIL has agreed to indemnify the Company and
its subsidiaries against the Everest & Jennings Proceedings in the event the
amount of losses, claims, demands, liabilities, damages and all related costs
and expenses (including attorney's fees and disbursements) in respect of the
Everest & Jennings Proceedings exceeds in the aggregate the applicable amounts
reserved for such proceedings on the books and records of Everest & Jennings as
of September 3, 1996. In view of BIL's obligation to indemnify the Company and
its subsidiaries with respect to such proceedings, management does not expect
that the ultimate liabilities, if any, with respect to such proceedings, will
have a material adverse effect on the consolidated financial position or results
of operations of the Company.
F-31
<PAGE> 71
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
13. COMMITMENTS AND CONTINGENCIES (CONTINUED)
On July 17, 1990, a class action suit was filed in the United States District
Court for the Central District of California by a stockholder of Everest &
Jennings against Everest & Jennings and certain of its present and former
directors and officers. The suit seeks unspecified damages for alleged
non-disclosure and misrepresentation concerning Everest & Jennings in violation
of federal securities laws. The district court dismissed the complaint on March
26, 1991, and plaintiff filed his first amended complaint on May 8, 1991. The
district court again granted a motion to dismiss the entire action on November
26, 1991. Plaintiff then took an appeal to the Ninth Circuit, which reversed the
district court's dismissal of the first amended complaint and remanded the case
to the district court for further proceedings. On March 25, 1996, the district
court granted Plaintiff's motion to certify a class composed of purchasers of
the Everest & Jennings' common stock during the period from March 31, 1989 to
June 12, 1990. Plaintiff's counsel has not as yet submitted to the court any
proposed notice of class certification and, consequently, the members of the
class have not been notified that the court has certified the case to proceed as
a class action. Everest & Jennings has received and filed responses and
objections to a document request, but further action has been deferred to allow
the parties to discuss possible settlement. Everest & Jennings has ordered the
parties to file and plaintiff's counsel has filed monthly reports on the status
of settlement discussions since September 1996. There are numerous defenses
which Everest & Jennings intends to assert to the allegations in the first
amended complaint if settlement cannot be reached on acceptable terms. Under
Everest & Jennings' directors and officers insurance policy, Everest & Jennings
has coverage against liabilities incurred by its directors and officers, subject
to a self-insured retention of $150,000 (which has been exceeded by defense
costs incurred to date). The carrier has contended that fifty percent of the
liability and expenses in the case must be allocated to Everest & Jennings,
which is not an insured defendant, and fifty percent to the insured former
director and officer defendants. This proceeding constitutes an Everest &
Jennings Proceeding, which is covered under BIL's indemnification obligations
pursuant to the terms and provisions of the Stockholder Agreement.
Die Cast Products, Inc., a former subsidiary of Everest & Jennings, was named as
a defendant in a lawsuit filed by the State of California pursuant to the
Comprehensive Environmental Response, Compensation and Liability Act 42
U.S.C. Sections 9601 et seq. Everest & Jennings was originally notified of
this action on December 10, 1992. A settlement was reached at an October 5, 1995
Mandatory Settlement Conference before Judge Rea in the Federal District Court
of the Central District of California. The state of California has agreed to
accept the sum of $2.6 million as settlement for all past costs and future
remedial work. Everest & Jennings' share of the settlement with the state of
California has amounted to $41,292.30, which sum was paid on January 3, 1997. No
further claims or assessments with respect to this matter are anticipated at
this time. This proceeding constitutes an Everest & Jennings Proceeding, which
is covered under BIL's indemnification obligations pursuant to the terms and
provisions of the Stockholder Agreement.
F-32
<PAGE> 72
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
13. COMMITMENTS AND CONTINGENCIES (CONTINUED)
In March, 1993, E&J received a notice from the U.S. Environmental Protection
Agency ("EPA") regarding an organizational meeting of generators with respect to
the Casmalia Resources Hazardous Waste Management Facility ("Casmalia Site") in
Santa Barbara County, CA. The EPA alleges that the Casmalia Site is an inactive
hazardous waste treatment, storage and disposal facility which accepted large
volumes of commercial and industrial wastes from 1973 until 1989. In late 1991,
the Casmalia Site owner/operator abandoned efforts to actively pursue site
permitting and closure and is currently conducting only minimal maintenance
activities. An agreement in principle now has been reached between the Casmalia
Steering Committee ("CSC") and the EPA for a settlement of the majority of the
Casmalia site liability. The Steering Committee represents approximately 50 of
the largest volume generators at the Casmalia site. It is anticipated that the
agreement will be formalized and embodied in a Consent Decree in the summer and
fall of 1997. Pursuant to the settlement, the CSC members are committing to
perform and fund Phase I work at the site. It is estimated that the Phase I work
being committed to will cost approximately $30 to $35 million dollars and will
take three to five years to complete. This cost will be allocated to Steering
Committee members based upon their volume of waste sent to the site. Everest &
Jennings accounts for 0.8% of the waste. Thus, by participating in the Phase I
settlement, Everest & Jennings has committed to payments of approximately
$280,000 to be spread over a three to five year period. Pursuant to the
settlement, Everest & Jennings will be released from further obligation for
thirty (30) years. In addition, the Steering Committee companies are seeking to
recover from the owner and operator of the site. Any such recovery will diminish
E&J's payout pursuant to the settlement. This proceeding constitutes an Everest
& Jennings Proceeding, which is covered under BIL's indemnification obligations
pursuant to the terms and provisions of the Stockholder Agreement.
In 1989, a patent infringement case was initiated against E&J and other
defendants in the U.S. District Court, Central District of California. E&J
prevailed at trial with a directed verdict of patent invalidity and
non-infringement. The plaintiff filed an appeal with the U.S. Court of Appeals
for the Federal Circuit. On March 31, 1993, the Court of Appeals vacated the
District Court's decision and remanded the case for trial. Impacting the retrial
of this litigation was a re-examination proceeding before the Board of Patent
Appeals with respect to the subject patent. A ruling was rendered November 23,
1993 sustaining the claim of the patent which E&J Inc. has been charged with
infringing. Upon the issuance of a patent re-examination certificate by the U.S.
Patent Office, the plaintiff presented a motion to the District Court requesting
a retrial of the case. E&J presented a Motion for Summary Judgment of
Noninfringement based in part upon the November 23, 1993 decision of the Board
of Patent Appeals. The Motion was granted in follow-up conferences and an
official Judgment was entered November 17, 1994. Following the appeal by the
plaintiffs, the case has been remanded to the U.S. District Court, Central
District of California, for further consideration. E&J believes that this case
is without merit and intends to contest it vigorously. The ultimate liability of
E&J, if any, cannot be determined at this time. This proceeding constitutes an
Everest & Jennings Proceeding, which is covered under BIL's indemnification
obligations pursuant to the terms and provisions of the Stockholder Agreement.
F-33
<PAGE> 73
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
13. COMMITMENTS AND CONTINGENCIES (CONTINUED)
Following a jury trial on July 15, 1996, a verdict was rendered in the District
Court of the First Judicial District of the State of New Mexico in a civil
product liability law suit (Chris Trew et al. vs. Smith and Davis Manufacturing
Company, Inc., No. SF95-354) against Smith & Davis Manufacturing Company, a
wholly-owned subsidiary of Everest & Jennings ("Smith & Davis"), in the amount
of $635,698.12 actual damages, prejudgment interest and costs, plus $4 million
punitive damages. The suit was instituted on February 25, 1995 by the children
and surviving heirs and personal representatives of a nursing home patient in
Carlsbad, New Mexico who died on September 28, 1993 after her head became pinned
between a bed rail allegedly manufactured by Smith & Davis and her bed. The suit
alleged that the bed rail in question was defective and unsafe for its intended
purpose, that Smith & Davis was negligent in designing, manufacturing, testing
and marketing such bed rails, and that the negligence of the nursing home in
question was the proximate cause of decedent's injuries and death. The nursing
home reached a settlement with Plaintiffs prior to trial. Judgment was entered
on the jury verdict, which bears interest at the rate of 15% from August 30,
1996 until paid. On October 15, 1996, Plaintiffs filed a related case in the
Circuit Court of the County of St. Louis, Missouri (Chris Trew, et. al. v.
Everest & Jennings, et al., Cause No. 96CC-000456, Division 39), which seeks a
declaratory judgment against Everest & Jennings and BIL to pierce their
respective corporate veils and holding them jointly and severally liable for the
full amount of the New Mexico judgment. On February 26, 1997, the parties agreed
in principle to a proposed settlement in which the Plaintiffs would receive $3
million, of which Everest & Jennings estimates that approximately $1.5 million
will be paid by Everest & Jennings' insurance carriers, however, Everest &
Jennings may seek additional recovery from the insurance carriers. The amounts
required to be paid in the proposed settlement in excess of any insurance
recoveries will be borne, in whole or in part, by BIL under the indemnification
terms and provisions contained in the Stockholder Agreement and/or through the
Company's right of offset under the BIL Note.
While the results of the lawsuits and other proceedings referred to above
cannot be predicted with certainty, management does not expect that the
ultimate liabilities, if any, will have a material adverse effect on the
consolidated financial position, results of operations or cash flows of the
Company.
The Company and its subsidiaries are parties to other lawsuits and other
proceedings arising out of the conduct of its ordinary course of business,
including those relating to product liability and the sale and distribution of
its products. While the results of such lawsuits and other proceedings cannot be
predicted with certainty, management does not expect that the ultimate
liabilities, if any, will have a material adverse effect on the consolidated
financial position, results of operations or cash flows of the Company.
COLLECTIVE BARGAINING AGREEMENTS
The Company is a party to five (5) collective bargaining agreements covering the
Company's facilities located in Hauppauge, New York; Passaic, New Jersey; Earth
City, Missouri; Ontario, Canada; and Guadalajara, Mexico. The collective
bargaining agreements cover approximately 620 employees. The collective
bargaining agreements for Hauppauge, New York; Passaic, New Jersey; Earth City,
Missouri; Ontario, Canada; and Guadalajara, Mexico are scheduled to expire on
September 30, 1997, July 27, 1999, September 13, 1999, July 24, 1998 and
December 31, 1997, respectively.
The Company has never experienced an interruption or curtailment of operations
due to labor controversy, except for a three-day period during the summer of
1993 in which the Company experienced a strike at its Passaic, New Jersey
facility, which did not have a material adverse effect on the Company's
operations. The Company considers its employee relations to be satisfactory.
F-34
<PAGE> 74
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
14. OTHER MATTERS
During the fourth quarter of 1996, the Company recorded charges of $15,800,000
related to the acquisition of Everest & Jennings. The charges included
$12,800,000 related to the write-off of purchased in-process research and
development costs (see Note 2) and $3,000,000 for other merger related charges
(see Note 2).
In addition, the Company recorded an extraordinary item of $736,000 (net of tax
benefit of $383,000) related to the early extinguishment of the John Hancock
Indebtedness in the fourth quarter of 1996 (see Note 8).
During the fourth quarter of 1994, the Company recorded non-recurring expenses
of approximately $1,321,000 which were included in selling, general and
administrative expenses at December 31, 1994, of which approximately $612,000
was included in accrued expenses. These non-recurring expenses were related to
the estimated impairment of the residual value related to the Company's
investment in leveraged lease (see Note 5), an accrual for severance and other
employee costs related to employees terminated during the fourth quarter of 1994
and first quarter of 1995, an accrual for sales and franchise taxes related to
in process audits being conducted by multiple states for the periods of 1988
through 1992, and costs related to a terminated acquisition attempt and a lease
arbitration proceeding with respect to the Company's principal manufacturing
facility.
15. MAJOR CUSTOMERS
In 1994, the Company derived approximately 10% of its revenues from Apria
Healthcare Group, Inc. (formerly Abbey Home Healthcare, which merged with
Homedco in June 1995). On September 1, 1995, the Company announced that its
current supply agreement with Apria would not be renewed in 1996, and will
expire by its terms on December 31, 1995. During fiscal year 1995 and 1994, the
Company's product sales to Apria were approximately $8.1 million and $10.3
million, respectively, which represented approximately 7% and 10%, respectively,
of the Company's product sales. The Company's sales to Apria generate gross
profit margins of approximately 20%, which is significantly lower than the
Company's sales to its other customers which generate gross profit margins of
approximately 33%. During 1996, no single customer or buying group accounted for
more than 10% of the Company's revenues.
16. SUBSEQUENT EVENTS
On February 28, 1997, Everest & Jennings Canada acquired substantially all of
the assets and certain liabilities of Motion 2000 Inc. and its wholly-owned
subsidiary, Motion 2000 Quebec Inc., for a purchase price equal to Cdn. $2.9
million (Canadian Dollars) (approximately $2.15 million). The purchase price was
paid by the issuance of 187,733 shares of the common stock of the Company valued
at $11.437 per share, of which 28,095 shares were delivered into escrow. The
purchase price is subject to adjustment if the final determination of the
closing date net book value of the assets acquired by Everest & Jennings Canada
is equal to or less than Cdn. $450,000 (Canadian Dollars) (approximately
$333,000). All of the escrowed shares will be held in escrow until the earlier
to occur (the "Initial Release Date") of June 28, 1997, or the final resolution
of the purchase price. On the Initial Release Date, a portion of the escrowed
shares will be released in an amount equal to the difference between (i) 28,095
shares and (ii) the sum of the number of (x) any escrowed shares subject to any
indemnification claims, (y) any escrowed shares used to satisfy any adjustment
to the purchase price, and (z) 18,729 shares. The balance of the escrowed shares
will be released on December 31, 1997, subject to any claims for
indemnification.
F-35
<PAGE> 75
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
16. SUBSEQUENT EVENTS (CONTINUED)
On March 7, 1997, E&J acquired Kuschall of America, Inc., a manufacturer of
pediatric wheelchairs, high-performance adult wheelchairs and other
rehabilitation products, for a purchase price of $1,510,000, representing the
net book value of Kuschall. The purchase price was paid by the issuance of
116,154 shares of the common stock of the Company valued at $13.00 per share, of
which 23,230 shares were delivered into escrow. The escrow shares will be
released on March 7, 1999, subject to any purchase price adjustments in favor of
the Company and claims for indemnification.
F-36
<PAGE> 76
SCHEDULE II--VALUATION AND QUALIFYING ACCOUNTS
GRAHAM-FIELD HEALTH PRODUCTS, INC. AND SUBSIDIARIES
<TABLE>
<CAPTION>
COL. A COL. B COL. C COL. D COL. E
ADDITIONS
- ------------------------------------------------- ------------ ----------------------------- --------------- ------------
1 2
BALANCE AT ADDITIONS OTHER CHANGES-- BALANCE AT
BEGINNING CHARGED TO COSTS CHARGED TO OTHER ADD (DEDUCT)-- END OF
DESCRIPTION OF PERIOD AND EXPENSES ACCOUNTS-DESCRIBE DESCRIBE PERIOD
- ------------------------------------------------- ------------ ------------ -------------- --------------- ------------
<S> <C> <C> <C> <C> <C>
Allowance for doubtful accounts:
Year Ended December 31, 1996 $ 1,811,000 $ 606,000 $ 5,077,000(2) $ (251,000)(1) $ 7,243,000
Year ended December 31, 1995 1,987,000 451,000 10,000(2) (637,000)(1) 1,811,000
Year ended December 31, 1994 2,564,000 595,000 (1,172,000)(1) 1,987,000
Valuation allowance for net deferred tax assets:
Year ended December 31, 1996 $ 55,000 $ 1,000,000 $ 14,494,000(2) -- $ 15,549,000
Year Ended December 31, 1995 55,000 -- -- -- 55,000
Year Ended December 31, 1994 55,000 -- -- -- 55,000
</TABLE>
(1) Net write-offs of accounts receivable.
(2) Represents an allocation of the purchase price of the Everest &
Jennings and V.C. Medical acquisitions.
F-37
<PAGE> 77
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA:
The response to this Item is submitted as a separate section of this
Report.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURES:
None.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT:
EXECUTIVE OFFICERS OF THE REGISTRANT
The Company's executive officers are elected by, and serve at the
discretion of the Board of Directors. The following table sets forth certain
information concerning the present executive officers of the Company:
Position(s) with Year Became
Name Age Company Executive Officer
- ------------------------ --- -------------------------- -----------------
Irwin Selinger 56 Chairman of the 1981
Board and Chief
Executive Officer
Gary M. Jacobs 39 Vice President - Finance 1992
and Chief Financial Officer
Richard S. Kolodny 38 Vice President, General 1993
Counsel, and Secretary
Peter Winocur 41 Executive Vice President 1996
of Sales and Marketing
Ralph Liguori 51 Executive Vice President 1995
of Operations
Beatrice Scherer 58 Vice President - Administration 1981
Donald J. Cantwell 47 Vice President of Information 1997
Systems
-76-
<PAGE> 78
Mr. Selinger, a founder and principal stockholder of the Company, has
been the Chairman of the Board and Chief Executive Officer of the Company since
April 1981. Mr. Selinger was a founder and the Chief Executive Officer of
Surgicot, Inc., a manufacturer of sterilization indicators, and its predecessor
from 1968 to April 1980. In 1979, Surgicot, Inc. was acquired by E. R. Squibb &
Sons, Inc., a subsidiary of Squibb Corporation. From April 1980 to June 1984,
Mr. Selinger was a consultant to E. R. Squibb & Sons, Inc.
Mr. Jacobs has been Vice President-Finance and the Chief Financial
Officer of the Company since August 1992. Since 1979, Mr. Jacobs was employed by
the accounting firm of Ernst & Young LLP, and most recently, held the position
of senior manager.
Mr. Kolodny has been Vice President, General Counsel and Secretary of
the Company since August 1993. From 1990 to 1993, Mr. Kolodny was associated
with the law firm of Carro, Spanbock, Kaster & Cuiffo. Prior to such time, Mr.
Kolodny was associated with the law firm of Shea & Gould.
Mr. Winocur has held various positions with the Company since May 1992,
and has been the Executive Vice President of Sales and Marketing of the Company
since January 1996. Prior to 1992, Mr. Winocur was the founder and President of
National Health Care Equipment, Inc., which was acquired by the Company in May
1992.
Mr. Liguori has been the Executive Vice President of Operations of the
Company since July 1995. From 1990 to 1995, Mr. Liguori was the Group Vice
President of Operations of Del Laboratories, Inc. Prior to such time, Mr.
Liguori was the Senior Vice President of U.S. Operations of Coleco Industries,
Inc.
Ms. Scherer has been Vice President-Administration of the Company since
1985. From 1981 to 1985, Ms. Scherer was Vice-President-Finance for the Company.
Mr. Cantwell has been the Vice President of Information Systems of the
Company since May 1996, and became an executive officer of the Company as of
January 1, 1997. From 1995 to 1996, Mr. Cantwell was the Chief Information
Officer of Dial-A-Mattress, Inc. Prior to such time, Mr. Cantwell held various
management positions with Grumman Corporation for over ten years.
The information to be furnished with respect to the directors of the
Company is incorporated by reference to the Company's definitive proxy statement
to be filed pursuant to Regulation 14A.
ITEM 11. EXECUTIVE COMPENSATION:
Incorporated by reference to the Company's definitive proxy statement
to be filed pursuant to Regulation 14A.
-77-
<PAGE> 79
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT:
Incorporated by reference to the Company's definitive proxy statement
to be filed pursuant to Regulation 14A.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS:
Incorporated by reference to the Company's definitive proxy statement
to be filed pursuant to Regulation 14A.
-78-
<PAGE> 80
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENTS, SCHEDULES AND REPORTS ON FORM 8-K.
14(a). Documents filed as part of this Form 10-K:
1. Financial Statements. The following financial statements are
included in Part II, Item 8:
Page
Report of Independent Auditors F-2
Consolidated Balance Sheets -- December 31, 1996 and 1995 F-3
Consolidated Statements of Operations -- Years ended
December 31, 1996, 1995 and 1994 F-5
Consolidated Statements of Stockholders' Equity --
Years ended December 31, 1996, 1995 and 1994 F-6
Consolidated Statements of Cash Flows -- Years ended
December 31, 1996, 1995 and 1994 F-7
Notes to Consolidated Financial Statements --
December 31, 1996 F-9
2. Financial Statement Schedules. The following
consolidated financial statement schedule for the
company is included in Part II, Item 14(d):
Schedule VIII--Valuation and Qualifying Accounts F-37
All other schedules for which provision is made in the applicable
accounting regulation of the Securities and Exchange Commission
are not required under the related instructions or are
inapplicable, and therefore have been omitted.
3. Exhibits filed under Item 601 of Regulation S-K. (Numbers
assigned to the following correlate to those used in such
Item 601; asterixes indicate that an Exhibit is incorporated
by reference).
3. (a) The Company's Certificate of Incorporation, as amended, *
is incorporated by reference to Exhibit 3(1) to the Company's
Registration Statement on Form S-1 (File No. 33-40442) (the
"1991 Registration Statement").
- -----------------------
* Incorporated by reference.
-79-
<PAGE> 81
(b) Certificate of Amendment of Certificate of Incorporation
of the Company dated as of November 27, 1996.
(c) Certificate of Merger dated as of November 27, 1996, by
and between E&J Acquisition Corp. and Everest & Jennings
International Ltd.
(d) The Company's By-Laws, as amended, are incorporated by *
reference as an Exhibit to the Company's Current Report on
Form 8-K dated as of July 14, 1995.
4. (a) Certificate of Designations of the Company's Series B *
Cumulative Convertible Preferred Stock is incorporated by
reference to Annex D to the Company's S-4 Registration
Statement filed on October 18, 1996 (Registration No.
333-14423) (the "1996 S-4 Registration Statement").
(b) Certificate of Designations of the Company's Series C *
Cumulative Convertible Preferred Stock is incorporated by
reference to Annex E to the 1996 S-4 Registration Statement.
(c) Certificate of Designations of Series A Junior *
Participating Preferred Stock, is incorporated by reference
to Exhibit 4(c) to the Company's Report on Form 8-K dated as
of September 3, 1996 (the "1996 Form 8-K").
(d) Rights Agreement dated as of September 3, 1996 between *
the Company and American Stock Transfer & Trust Company, as
Rights Agent (the "1996 Rights Agreement") is incorporated by
reference to Exhibit 4(b) to the 1996 Form 8-K.
10. (a) Supply Agreement dated as of October 15, 1996, between
Healthtech Products, Inc., Invacare Corporation and Everest &
Jennings, Inc.
(b) Supply Agreement, by and between Everest & Jennings, Inc.
and P.T. Dharma Polimetal.
(c) Employment Agreement dated as of July 8, 1981 (the *
"Selinger Agreement"), between the Company and Irwin
Selinger is incorporated by reference to Exhibit 10(a) to the
Company's Registration Statement on Form S-18 (Registration
No. 2-80107-NY).
(d) Amendment to the Selinger Agreement dated as of July 8, *
1991, is incorporated by reference to Exhibit 10.1 to the
1991 Registration Statement.
(e) Amendment to the Selinger Agreement dated as of May 3,
1996.
(f) Agreement dated June 6, 1986 between the Company and *
Gould Investors, LP with respect to the sale and leaseback
of 400 Rabro Drive, Hauppauge, NY is incorporated by
reference to Exhibit 10(rr) to the Company's Annual Report on
Form 10-K for the year ended December 31, 1986 (the "1986
10-K").
* Incorporated by reference.
-80-
<PAGE> 82
(g) Second Amendment to Lease, dated January 1, 1990, between *
the Company and Gould Investors, L.P. in incorporated by
reference to Exhibit 10(ii) to the Company's Annual Report on
Form 10-K for the year ended December 31, 1990 (the "1990
10-K").
(h) Lease dated January 1, 1987, between the Company and *
R-Three Investors with respect to the renting of 30,000
square feet at 135 Fell Court, Hauppauge, is incorporated by
reference to Exhibit 10(tt) to the 1986 10-K.
(i) Lease Extension Agreement, dated March 8, 1990 between *
the Company and R-Three Investors with respect to the
renting of 30,000 square feet at 135 Fell Court, Hauppauge is
incorporated by reference to Exhibit 10(hh) to the 1990 10-K.
(j) Lease Agreement dated as of March 19, 1992, by and
between NET 2, L.P. and Everest & Jennings, Inc.
(k) Lease Agreement dated as of October 1, 1991 (the "Temco *
Lease Agreement"), by and between TEMCO National Corp. and
Graham-Field, Inc. is incorporated by reference to Exhibit
10(ee) to the Company's Annual Report on Form 10-K for the
year ended December 31, 1991 (the "1991 10-K").
(l) Modification of Temco Lease Agreement dated as of May 18, *
1992, by and between TEMCO National Corp. and Graham-Field
Temco, Inc. is incorporated by reference to Exhibit 10(dd) to
the Company's Annual Report on Form 10-K for the Year ended
December 31, 1992 (the "1992 10-K").
(m) Amendment No. 2 to Temco Lease Agreement dated as of *
April 13, 1994, by and between The Wendt-Bristol Health
Services Corporation and Graham-Field Temco, Inc. is
incorporated by reference to Exhibit 10(x) to the Company's
Annual Report on Form 10-K for the year ended December 31,
1995 (the "1995 10-K").
(n) Amendment No. 3 to Temco Lease Agreement dated as of May *
1, 1995, by and between The Wendt-Bristol Health Services
Corporation and Graham-Field Temco, Inc. is incorporated by
reference to Exhibit 10(y) to the 1995 10-K.
(o) Lease Agreement dated as of March 23, 1992, by and *
between The Equitable Life Assurance Society of the United
States and Graham-Field, Inc. is incorporated by reference to
Exhibit 10(ff) to the 1991 10-K.
(p) Lease Agreement dated as of March 21, 1996, by and *
between Graham-Field, Inc. and HIP Realty, Inc. is
incorporated by reference to Exhibit 10(jj) to the 1995 10-K.
(q) Lease Agreement dated as of April 10, 1996, by and
between the Company and Stone Mountain Industrial Park, Inc.
* Incorporated by reference.
-81-
<PAGE> 83
(r) Lease Agreement dated as of August 1, 1996, by and
between Owen Bros. Enterprises and Bobeck Medical
Distribution.
(s) Assignment, Assumption and Consent Agreement dated as of
January 27, 1997 by and among Bobeck Medical Distribution,
Owen Bros. Enterprises and the Company.
(t) Lease Agreement dated as of September 19, 1996, by and
between J & M, S.E. and Graham-Field Express (Puerto Rico),
Inc.
(u) Lease Agreement dated as of December 27, 1996, by and
between Adaya Asset Washington, L.P. and Graham-Field, Inc.
(v) Lease Agreement dated as of February 27, 1997, by and
between Security Capital Industrial Trust and the Company.
(w) Union contract dated April 16, 1996, between Graham-Field
and Local 966 of International Brotherhood of Teamsters with
respect to the collective bargaining agreement at the
Hauppauge, New York facility.
(x) Union contract dated September 10, 1996, between
Graham-Field and Local 945 of International Brotherhood of
Teamsters with respect to the collective bargaining agreement
at the Temco, New Jersey facility.
(y) Union contract dated July 24, 1996, between Everest &
Jennings Canadian Limited and the United Steelworkers' of
America on behalf of its Local 5338.
(z) Union contract dated September 13, 1996, between Everest
& Jennings Inc. and District No. 9, International Association
of Machinists and Aerospace Workers.
(aa) The Incentive Program is incorporated by reference to *
the Company's Registration Statements on Form S-8 (File
Nos. 33-37179, 33-38656, 33-48860, 033-60679 and 333-16993).
(bb) Amendment No. 1 to the Incentive Program is incorporated *
by reference to Exhibit A to the Company's Proxy Statement
dated as of May 10, 1991.
(cc) Amendment No. 2 to the Incentive Program is incorporated *
by reference to Exhibit A to the Company's Proxy Statement
dated as of May 14, 1992.
(dd) Amendment No. 3 to the Incentive Program dated as of *
January 28, 1993 is incorporated by reference to Exhibit
10(y) to the 1992 10-K.
(ee) Amendment No. 4 to the Incentive Program dated as of *
June 20, 1995 is incorporated by reference to Exhibit 4 to
the Company's Registration Statement on Form S-8 (File No.
033-60679).
(ff) Amendment No. 5 to the Incentive Program dated as of *
December 21, 1995 is incorporated by reference to Exhibit
10(s) to the 1995 10-K.
* Incorporated by reference.
-82-
<PAGE> 84
(gg) Amendment No. 6 to the Incentive Program dated as of *
November 27, 1996 is incorporated by reference to Exhibit 4
to the Company's Registration Statement on Form S-8 (File No.
333-16993).
(hh) Agreement and Plan of Merger dated as of May 9, 1991, by *
and among Horizon International Healthcare, Inc., Aquatherm
Acquisition Corp., Graham-Field, Inc., the Company, Tyler
Schueler and John Shepherd is incorporated by reference to
Exhibit 10 (cc) to the Company's 1991 10-K.
(ii) Asset Purchase Agreement dated as of August 30, 1991, by *
and between TEMCO National Corp. and Graham-Field, Inc. is
incorporated by reference to Exhibit (c)(1) to the Company's
Current Report on Form 8-K dated as of October 12, 1991.
(jj) John Hancock Mutual Life Insurance Note and Warrant *
Agreement dated as of March 12, 1992 is incorporated by
reference to Exhibit 10(ee) to the 1992 10-K.
(kk) Amendment dated as of December 31, 1992, to the John *
Hancock Mutual Life Insurance Note and Warrant Agreement is
incorporated by reference to Exhibit 10(ff) to the 1992 10-K.
(ll) Amendment dated as of June 30, 1993, to the John Hancock *
Mutual Life Insurance Note and Warrant Agreement is
incorporated by reference as an Exhibit to the Company's
Quarterly Report on Form 10-Q for the quarter ended September
30, 1993.
(mm) Amendment dated as of December 31, 1993, to the John *
Hancock Mutual Life Insurance Note and Warrant Agreement is
incorporated by reference to Exhibit 10(dd) to the Company's
Annual Report on Form 10-K for the year ended December 31,
1993.
(nn) Amendment dated as of December 30, 1994, to the John *
Hancock Mutual Life Insurance Note and Warrant Agreement is
incorporated by reference to Exhibit 10(ee) to the Company's
Annual Report on Form 10-K for the year ended December 31,
1994.
(oo) Asset Purchase Agreement dated as of May 28, 1993, by *
and among Graham-Field, Inc., Diamond Medical Equipment
Corp., National Health Care Equipment, Inc., Harvey Diamond
and Peter Winocur is incorporated by reference to Exhibit
(c)(1) to the Company's Current Report on Form 8-K dated as
of June 5, 1992.
(pp) Asset Purchase Agreement dated as of September 22, 1995, *
by and among Graham-Field Health Products, Inc., National
Medical Excess Corp. and John Wittenberg is incorporated by
reference to Exhibit 10(gg) to the 1995 10-K.
* Incorporated by reference.
-83-
<PAGE> 85
(qq) Asset Purchase Agreement dated as of March 4, 1996, by *
and between Graham-Field, Inc. and the Lumiscope Company,
Inc. is incorporated by reference to Exhibit 10(hh) to the
1995 10-K.
(rr) Rights Agreement dated as of September 3, 1996 between *
the Company and American Stock Transfer & Trust Company, as
Rights Agent (the "1996 Rights Agreement") is incorporated by
reference to Exhibit 4(b) to the Company's Report on Form 8-K
dated as of September 3, 1996.
(ss) Registration Rights Agreement, dated as of September 3, *
1996, between the Company and BIL is incorporated by
reference to Exhibit 4(g) to the Company's Report on Form 8-K
dated as of September 3, 1996.
(tt) Amended and Restated Agreement and Plan of Merger dated *
as of September 3, 1996, and amended as of October 1, 1996,
by and among the Company, E&J Acquisition Corp., Everest &
Jennings International Ltd. and BIL is incorporated by
reference to Exhibit 2(a) to the Company's Report on Form 8-K
dated as of December 12, 1996.
(uu) Stockholder Agreement, dated as of September 3, 1996, *
and amended and restated as of October 1, 1996, among the
Company, BIL and Irwin Selinger is incorporated by reference
to Exhibit 4(b) to the Company's Report on Form 8-K dated as
of December 12, 1996.
(vv) Promissory Note dated as of December 10, 1996, in the
principal amount of $4 million made by the Company and
payable to BIL Securities (Offshore) Limited.
(ww) Asset Purchase Agreement dated as of September 4, 1996, *
by and among the Company, Graham-Field Express (Puerto
Rico), Inc. ("GFPR"), and V.C. Medical Distributors, Inc. is
incorporated by reference to Exhibit 2(a) to the Company's
Report on Form 8-K dated as of September 17, 1996.
(xx) Revolving Credit and Security Agreement dated as of *
December 10, 1996 (the "Revolving Credit Agreement"), by
and among IBJ Schroder Bank & Trust Company (as lender and as
agent), the Company, Graham- Field, Inc., Graham-Field
Express, Inc., Graham-Field Temco, Inc., Graham-Field
Distribution, Inc., Graham-Field Bandage, Inc., Graham-Field
Express (Puerto Rico), Inc., and Everest & Jennings, Inc. is
incorporated by reference to Exhibit 10 to the Company's
Report on Form 8-K dated as of December 23, 1996.
(yy) Asset Purchase Agreement dated as of February 10, 1997, *
by and among the Company, Everest & Jennings Canadian
Limited ("E&J Canada"), Motion 2000 Inc. ("Motion 2000"), and
Motion 2000 Quebec Inc. ("Motion Quebec") is incorporated by
reference to Exhibit 2(a) to the Company's Report on Form 8-K
dated as of March 12, 1997.
* Incorporated by reference.
-84-
<PAGE> 86
(zz) Stock Purchase Agreement dated as of March 7, 1997, by *
and among the Company, Everest & Jennings, Inc., Michael H.
Dempsey, and Naomi C. Dempsey is incorporated by reference to
Exhibit 2(a) to the Company's Report on Form 8-K dated as of
March 20, 1997.
* Incorporated by reference.
-85-
<PAGE> 87
22. Subsidiaries of the Company:
Labtron Scientific Corporation
(a New York corporation)
Patient Technology, Inc.
(a New York corporation)
Graham-Field Express, Inc.
(a Delaware corporation)
Bristoline, Inc.
(a New York corporation)
Ventilator Corp.
(a New York corporation)
Graham-Field, Inc.
(a New York corporation)
Medisco, Inc.
(a Delaware corporation)
ExNewt, Inc.
(a New York corporation)
M.E. Team, Inc.
(a New Jersey corporation)
Graham-Field Temco, Inc.
(a New Jersey corporation)
AquaTherm Corp.
(a New Jersey corporation)
Health and Medical Techniques, Inc.
(a Connecticut corporation)
Graham-Field Distribution, Inc.
(a Missouri corporation)
Graham-Field Bandage, Inc.
(a Rhode Island corporation)
G.F.E. Healthcare Products Corp.
(a Delaware corporation)
Graham-Field European Distribution
Corporation Limited
(an Ireland corporation)
HealthTeam, Inc.
(a Delaware corporation)
Graham-Field Express (Puerto Rico), Inc.
(a Delaware corporation)
Graham-Field Express (Dallas), Inc.
(a Delaware corporation)
Everest & Jennings International Ltd.
(a Delaware corporation)
Everest & Jennings, Inc.
(a California corporation)
Smith & Davis Manufacturing Company
-86-
<PAGE> 88
(a Missouri corporation)
Everest & Jennings de Mexico S.A. de C.V.
(a Mexico corporation)
The Jennings Investment Company
(a California corporation)
Everest & Jennings Canadian Ltd.
(a Canadian corporation)
MCT Acquisition Corp.
(a Missouri corporation)
Thompson Blair, Inc.
(a Missouri corporation)
Freeway Investment Corp.
(a California corporation)
Metal Products Corp.
(a California corporation)
Professional Securities Corp.
(a Missouri corporation)
International Medical Equipment Corp.
(a California corporation)
Everest & Jennings Lifestyles
(a California corporation)
Rabson Medical Sales, Ltd.
(a New York corporation)
Kuschall of America, Inc.
(a California corporation)
24. Consent of Independent Auditors.
14(b). Reports on Form 8-K.
The Company's Report on Form 8-K dated as of December 12, 1996 (Date of
Event: November 27, 1996).
The Company's Report on Form 8-K dated as of December 23, 1996 (Date of
Event: December 10, 1996).
-87-
<PAGE> 89
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this amendment to be signed
on its behalf by the undersigned, thereunto duly authorized.
GRAHAM-FIELD HEALTH PRODUCTS, INC.
By: /s/ Richard S. Kolodny
--------------------------------------
Richard S. Kolodny, Vice President,
Gereral Counsel and Secretary
Date: December 19, 1997
